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ABSTRACT: A novel series of potent chiral inhibitors of histone deacetylase (HDAC) is
described that contains an oxazoline capping group and a N-(2-aminophenyl)-benzamide
unit. Among several new inhibitors of this type exhibiting Class I selectivity and potent
inhibition of HDAC3-NCoR2, in vitro assays for the inhibition of HDAC1, HDAC2, and
HDAC3-NCoR2 by N-(2-aminophenyl)-benzamide 15k gave respective IC50 values of 80,
110, and 6 nM. Weak inhibition of all other HDAC isoforms (HDAC4, 5, 6, 7, and 9: IC50
> 100 000 nM; HDAC8: IC50 = 25 000 nM; HDAC10: IC50 > 4000 nM; HDAC11: IC50 >
2000 nM) conﬁrmed the Class I selectivity of 15k. 2-Aminoimidazolinyl, 2-thioimidazolinyl, and 2-aminooxazolinyl units were
shown to be eﬀective replacements for the pyrimidine ring present in many other 2-(aminophenyl)-benzamides previously
reported, but the 2-aminooxazolinyl unit was the most potent in inhibiting HDAC3-NCoR2. Many of the new HDAC inhibitors
showed higher solubilities and lower binding to human serum albumin than that of Mocetinostat. Increases in histone H3K9
acetylation in the human cell lines U937 and PC-3 was observed for all three oxazolinyl inhibitors evaluated; those HDAC
inhibitors also lowered cyclin E expression in U937 cells but not in PC-3 cells, indicating underlying diﬀerences in the
mechanisms of action of the inhibitors on those two cell lines.
■ INTRODUCTION
Epigenetic mechanisms1 are relevant to a wide range of diseases
including cancer, diabetes, heart disease, and neurological
disorders. At physiological pH, the alkylammonium units that
form upon deacetylation of the ε-amino group of lysine
residues in histone proteins bind closely to the negatively
charged DNA phosphate groups. Hypoacetylation arising from
increased histone deacetylase (HDAC) activity results in
chromatin compaction and therefore transcriptional repression
and aberrant gene regulation associated with precancerous or
malignant states.2−4 Inhibitors of histone deacetylase
(HDAC)5,6 have been much studied as a means of epigenetic
cancer therapy5,6 and can be eﬀective in the treatment of
certain leukemias, partly through relief of transcriptional
repression.7,8 HDAC inhibitors also reduce cancer cell
proliferation by induction of cell cycle arrest, diﬀerentiation,
and/or apoptosis.9−12 Class I HDAC inhibitors, especially
HDAC1, HDAC2, and HDAC3, are considered to be key
targets for cancer treatment.
Although Romidepsin, a macrocyclic peptide containing a
disulﬁde bridge, is a potent HDAC inhibitor used in the
treatment of cutaneous T-cell lymphoma,13 most Class I
HDAC inhibitor anticancer agents5,6 are of two structural
types: (1) hydroxamic acids, including Vorinostat (suberoyla-
nilide hydroxamic acid) used in the treatment of cutaneous T-
cell lymphoma,14 Belinostat used to treat peripheral T-cell
lymphoma,15 and Panobinostat for the treatment of multiple
myeloma;16 and (2) aminoanilides (Figure 1) such as
Chidamide,17 approved in China for the treatment of pancreatic
cancer, Mocetinosat, in clinical trials for the treatment of
myelogenous leukemia,18,19 and Entinostat (MS-275), which
was in Phase I clinical trials for the treatment of metastatic
melanoma.20 Additionally, the HDAC3-selective inhibitor
RGFP966 has been studied for its eﬀect on cutaneous T-cell
lymphoma.21 Given the limitations of in vivo eﬃcacy and
toxicity observed with many hydroxamic acids, new amino-
anilide inhibitors could be expected to show prolonged
inhibitory eﬀects and longer intervals between dosing:22,23 for
example, the slow, tight binding22 of Mocetinostat to HDACs
and its slow decomplexation may be signiﬁcant factors for its
eﬀects, and the observation of a lack of acquired resistance to
Mocetinostat may be a potential advantage.24 Among amino-
anilide Class I HDAC inhibitors, the factors that govern
isoform selectivity have been little investigated, particularly the
eﬀect of chirality on the binding of inhibitors to various HDAC
isoforms. Herein are described the synthesis and preliminary
evaluation of a new series of aminoanilides that contain a chiral
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oxazoline unit and that possess speciﬁcity for HDAC3. HDAC3
is a requirement for hematopoietic stem/progenitor cells to
pass through S phase of the cell cycle and also for stem cell
function and lymphopoiesis.25 In various cancers, including
acute myelogenous leukemia25,26 and lymphoma,25,27 recruit-
ment of SMRT/N-CoR-HDAC3 complexes that induce
hypoacetylation leads to signiﬁcant transcriptional repression.
Additionally, HDAC3 is the target isoform associated with the
progressive neurodegenerative disease, Friedrich’s ataxia.28−30
■ CHEMISTRY
A series of analogues of Mocetinostat was sought that possessed
the same linker and zinc-binding group but a ﬁve-membered
heterocyclic replacement for the pyrimidine ring. Chirality
would be installed within the ﬁve-membered heterocycles that
also contain a heteroatom linker at the 2-position. A 2-
aminooxazolinyl unit was selected as a preferred potential
replacement in view of its low clogP (−0.53 cf. −0.22 for 2-
aminopyrimidine), high solubility, and established use in drug
design31 as well as the availability of a variety of enantiopure 2-
amino alcohols.
For comparison against the new oxazolinyl HDAC inhibitors,
selected ﬁve-membered rings with either 2-thiomethyl or 2-
aminomethyl linkages were prepared. S-Alkylation of (S)-4-
phenylimidazolidine-2-thione (4)32 with N-(2-aminophenyl)-4-
(chloromethyl)benzamide (1)33 in acetone at reﬂux aﬀorded
thioimidazoline 5 in 66% yield (Scheme 1), a succinct route
that did not require protection of the arylamino group.
Aminoimidazoline 8 was also prepared for purpose of
comparison. Since methods for the preparation of 2-
(alkylamino)imidazolines33 are limited, especially enantiopure
examples, a two-step approach was developed (Scheme 1).
Heating isothiocyanate 234 with diamine 3 in THF at reﬂux
aﬀorded thiourea 6 (57%), which was quantitatively cyclized in
acetone in the presence of iodomethane to give aminoimidazo-
line 7, which was deprotected using TFA in dichloromethane to
give the required aminoimidazoline 8 (47%).
A succinct route to the 2-(thiomethyl)oxazolines 11 was
developed, also without the need for protection of the
arylamino group (Scheme 2). Oxazolidine-2-thiones 10,
prepared by reaction of the 2-aminoalcohols 9 with carbon
disulﬁde in ethanol in the presence of K2CO3 at 50 °C followed
by treatment with hydrogen peroxide,35 underwent S-alkylation
with N-(2-aminophenyl)-4-(chloromethyl)benzamide (1)34 in
acetone at reﬂux to give the corresponding 2-(thiomethyl)-
oxazolines 11 (Scheme 2). With suitable ring systems now in
hand for comparison, attention was turned to the synthesis of
2-alkylaminooxazolines, the primary replacement motif.
Reaction of (2S)-2-amino-2-phenylethan-1-ol (12b)36 with
tert-butyl N-{2-[4-(isothiocyanatomethyl)benzamido]phenyl}-
carbamate (2) in THF aﬀorded thiourea (S)-13b (89%)
(Scheme 3).34 Yellow mercuric oxide has been used to cyclize
Figure 1. Examples of clinical HDAC inhibitors.
Scheme 1. a
aReagents and conditions: (a) CS2, NEt3, EtOH, H2O, 60 °C, 5 h,
then conc. HCl, reﬂux, 14 h, 31%; (b) 1, K2CO3, acetone, reﬂux, 17 h,
66%; (c) 2, THF, rt, 18 h, 57%; (d) iodomethane, acetone, rt, 18 h,
99% (crude); (e) TFA, DCM, rt, 2 h, 47%.
Scheme 2. a
aReagents and conditions: (a) CS2, K2CO3, EtOH, 50 °C, then H2O2,
5 min, 10a, 98%; 10b, 80%; 10c, 14%; (b) 1, K2CO3, acetone, reﬂux,
16−18 h, 11a, 70%; 11b, 47%; 11c, 45%.
Scheme 3. a
aReagents and conditions: (a) 2, THF, 20 °C, 16 h; (b) iodomethane
(2 equiv), acetone, 20 °C, 4−18 h; (c) yellow HgO (2.5−5 equiv) 1:2
ethanol/toluene, reﬂux, 0.5−4 h (13a, 13b); (d) TFA, CH2Cl2, 20 °C,
1.5−5.5 h.
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Table 1. In Vitro Inhibition of Histone Deacetylase Isoforms by Substituted Benzamides
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N-(β-hydroxyethyl)thioureas to the corresponding 2-amino-
4,5-dihydrooxazoles.37,38 However, (S)-13b did not cyclize to
(S)-14b using the conditions of Uchida.37 Accordingly,
Hirashima’s conditions38 were investigated, and modiﬁcation
of those using additional yellow mercuric oxide and a longer
reaction time proved to be eﬃcient, aﬀording (S)-14b in 76%
yield. The benzyl derivative (S)-14a was similarly prepared
(92%). In those reactions, it was found to be essential to use
freshly prepared yellow mercuric oxide in order to obtain
satisfactory yields; an aged commercial sample gave only low
yields of dihydrooxazoles (S)-14a and (S)-14b even after
extended reaction periods. Boc deprotection was achieved using
TFA in dichloromethane to give dihydrooxazoles (S)-15a and
(S)-15b in 47 and 74% yields, respectively (Scheme 3).
Although the above cyclizations of N-(β-hydroxyethyl)-
thioureas (S)-13a and (S)-13b using yellow mercuric oxide
were eﬀective, the need for several equivalents of this toxic
reagent led to a search for a more benign synthetic method.
One example of such a cyclization using iodomethane has been
described,39 and this method was found to be applicable to the
preparation of a wide variety of N-(β-hydroxyethyl)thioureas,
14c−l. Boc deprotection using TFA in dichloromethane
aﬀorded the corresponding dihydrooxazoles 15c−l.
■ RESULTS AND DISCUSSION
Of the few reports of alternative ring systems to the pyrimidine
ring in Mocetinostat, replacement has involved the use of only
planar, fused rings that decrease the solubility, albeit aﬀording
compounds with therapeutic potential.40 Several analogues with
planar rings in the capping group other than pyrimidine were
less potent against HDAC1 and several cell lines than was
Mocetinostat.41 SAR detail regarding the cap region of
Mocetinostat congeners has been limited, especially in regard
the potential inﬂuence of chirality; to our knowledge, there is
only one publication describing chiral heterocyclic cap
analogues of such aminoanilides.34
Our previous study34 showed that ﬁve-membered semi-
saturated ring systems such as imidazolin-4-one can be eﬀective
as a replacement for the pyrimidine ring in Mocetinostat and,
promisingly, even in the absence of the terminal 3-pyridyl ring
present in Mocetinostat. In the absence of a 3-pyridyl group,
few analogues of Mocetinostat (in which the pyrimidine ring
Table 1. continued
aAll IC50 values were obtained from experiments in triplicate.
bPercentage inhibition at 20 μM (from duplicate experiments). cPercentage inhibition
at 0.2 μM (from duplicate experiments).
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was retained) are potent HDAC inhibitors.41 Since the carbonyl
group of substituted imidazolin-4-ones rendered an adjacent
chiral center prone to racemization,34 1,2-dihydroazole units, as
pyrimidine replacements, became the focus of the present work.
The greater saturation of most 1,2-dihydroazoles and the
greater solubility of compounds with unsaturated oxazoline and
imidazoline rings compared to that of their pyrimidine
counterparts were additional potential advantages in improving
physicochemical properties.42
Comparison of the (4S)-4-phenyl-4,5-dihydro-1H-imidazole
derivative 8 with Mocetinostat (Table 1, entries 1 and 2) shows
that a smaller and partly saturated imidazoline ring system is
consistent with HDAC inhibition: its IC50 for HDAC3
inhibition showing 3-fold greater potency than Mocetinostat;
moreover, whereas inhibition of HDAC1, HDAC2, and
HDAC3-CoR2 by Mocetinostat is similar (and less than 5-
fold diﬀerent for isoforms 1 and 3), inhibition of HDAC3CoR2
by 8 is 16 times greater than HDAC1 and 18 times greater than
HDAC2. Comparison of entry 2 with entries 3−5 shows that
the 2-aminoalkyl substituent is important for potent HDAC3
inhibition, with the 2-thioalkyl compounds being appreciably
less potent.
For the 2-(arylmethylamino)-4-aryl-substituted dihydroox-
azole series, little variation in the potent inhibition of HDAC3-
CoR2 (IC50 = 24−40 nM) was found. However, the pair of
enantiomers 15b (entries 7 and 8) show that binding to
HDAC1 is signiﬁcantly inﬂuenced by the absolute conﬁg-
uration, with the (4R)-enantiomer being 6-fold more potent,
whereas inhibition of HDAC2 and HDAC3-CoR2 is little
aﬀected by the stereochemistry of the inhibitor. A similar
pattern is observed for the enantiomeric pair of 2-
(arylmethylamino)-5-aryl dihydrooxazoles 15h, with the (5R)-
enantiomer being 5-fold more potent at inhibiting HDAC1.
The simplest explanation for these results is that rotation about
the exocyclic C−N bonds permits the phenyl group of (R)-15b
to adopt the same orientation as that adopted by the phenyl
group in (R)-15h; the bonding of HDAC1 to the respective N
and O atoms of the heterocyclic rings does not appear to be the
determining factor. The enantiomeric pair 15h exhibit some
preferential inhibition: (S)-15h at HDAC2 and (R)-15h at
HDAC1.
The relatively bulky and diastereoisomeric 4,5-diphenyl-4,5-
dihydrooxazoles 15j and 15k are potent inhibitors of HDAC3-
CoR2, with 15k being the more potent and also with 13- and
18-fold selectivity over HDAC1 and HDAC2, respectively.
Compared to 15b, the additional phenyl ring present in 15k
increases by 5-fold the inhibition of HDAC3-CoR2. These
results are consistent with an extended lipophilic region that
can accommodate the cis-1,2-diphenyl unit.
Other features are also of note. Compared to (R)-15b, the p-
and m-ﬂuoro substituents in 15d and 15e have little eﬀect on
the inhibition of HDAC2 and HDAC3-CoR2. The terminal 3-
pyridyl capping group, present in Mocetinostat, is of little or no
advantage, as compared with phenyl, in these ﬁve-membered
heterocyclic systems (compare entries 4 and 5 and entries 7
and 13). The more ﬂexible benzyl substituent may confer
somewhat greater inhibition of HDAC1 and HDAC2 (entries 4
and 6 and entries 7 and 14) as compared with phenyl, but it
showed no advantage over phenyl in regard to inhibition of
HDAC3-CoR2. The same trends were observed for the 4-(1H-
imidazolylmethyl)-4,5-dihydrooxazole pair of enantiomers 15l
(entries 20 and 21).
The appreciable selectivity (up to 18-fold) for HDAC3 over
HDAC2 for several of the compounds in this work is
signiﬁcant, especially in view of the close homology of those
two isoforms. All compounds showed feeble inhibition of
HDAC6, consistent with the expected preference within Class I
HDAC isoform selectivity observed for other amino
anilides,18,27 and very low or negligible inhibition of HDAC8,
also as expected given previous studies.18 The Class I selectivity
of 15k, the most potent HDAC3 inhibitor (IC50 = 0.006 μM)
of this study, was further shown by evaluation against the Class
2 isoforms HDAC4, 5, 6, 7, and 9, with IC50 values for each
enzyme being >100 μM. Weak inhibition was observed for
HDAC8 (IC50 = 25 μM, Class 1) as well as little activity against
HDAC10 (IC50 > 2 μM, Class 2) and HDAC 11 (IC50 > 4 μM,
Class 4).
Physicochemical data (Table 2) for the ﬁve-membered
heterocyclic HDAC inhibitors are generally favorable, especially
with similar and in many cases higher solubilities and lower
binding to human serum albumin as compared to that of
Mocetinostat, with the exception of the relatively lipophilic
inhibitors 11a, 15d, and 15i−k. 3-Pyridyl compound 15c, the
oxazolinyl analogue of Mocetinostat, showed equipotent
inhibition of HDAC3-CoR2 but approximately 10-fold
selectivity over HDAC1 and HDAC2. HDAC inhibitors with
one aryl substituent at the 4- or 5-position of the oxazoline ring
showed suitable physicochemical properties (Table 2) and,
depending on the stereochemistry, high potency against
HDAC3-CoR2, usually with signiﬁcant isoform selectivity.
Table 2. Physicochemical Data of HDAC Inhibitors
compound
Chrom
log P
Chrom
log D7.4
solubility
CLND
(μg/mL)
permeability
(pH 7.4,
nm/s)
%HSA
binding
Mocetinostat 2.96 2.96 107 350 92.5
5 4.31 3.49 116 300 91.0
8 3.46 1.92 70a 17 72.2
11a 5.67 5.41 31 440 96.5
11c 3.32 3.19 108 270 87.5
15a 4.15 2.86 148a 230 85.9
(R)-15b 3.76 3.09 151a 310 84.7
(S)-15b 3.74 3.10 153a 330 85.3
15c 1.78 1.71 124a 33 68.7
15d 3.97 3.39 147 270 88.1
15e 3.84 3.42 131a 340 88.5
15f 4.72 4.54 8 360 94.3
15g 2.13 1.74 130a 13 74.4
(R)-15h 3.58 2.79 98 180 84.9
(S)-15h 3.84 2.99 77 162 89.9
15i 5.59 5.29 7 390 96.6
15j 5.41 5.01 6 410 96.9
15k 5.01 4.54 73 410 94.9
(R)-15l 0.93 0.89 158a <3 46.5
(S)-15l 0.95 0.90 142a <3 46.8
aGreater than or equal to the number shown. Chrom log D and
Chrom log P values43 and permeability (artiﬁcial membrane
permeability)44 were measured using procedures previously described.
Solubility was measured using chemiluminescent nitrogen detection
(CLND).45 Human serum albumin (HSA) binding was measured
using fast gradient HPLC with a chemically bonded protein stationary
phase.46
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■ BIOLOGY
Changes in histone acetylation status were assayed by analyzing
histone H3 acetylated on lysine 9 (H3K9Ac) upon addition of
N-(2-aminophenyl)-benzamides. To determine whether com-
pounds 15e, (S)-15h, (R)-15h, and Mocetinostat increase
histone H3 acetylation levels, the human cell lines U937 and
PC-3 were cultured in the presence of each compound (10
μM) or an equivalent volume of the diluent (DMSO) added as
the control. The cells were cultured for 24 h, and H3K9Ac was
analyzed by western blotting. The data show that at 10 μM
each of the above compounds caused an increase in histone
H3K9Ac with respect to histone H3 expression in U937 and
PC-3 cells. (Figure 1). These data are consistent with an
inhibition of endogenous cellular HDAC activity that causes net
acetylation of histone H3K9.
Previous studies showed that Mocetinostat causes an increase
in H3K9Ac in HeLa cells and leads to cell death by apoptosis.47
Consequently, in the present study, ﬂow cytometry analyses of
DNA and protein content of cells cultured with the compounds
were carried out to determine whether compounds 15e, (R)-
15h, and (S)-15h also cause apoptosis. The data obtained
(Figures 2−4) show that, for each of the compounds tested at
10 μM in both U937 and PC-3 cells, there is an increase in the
percentage of cells with sub-G1 DNA content, consistent with
induction of apoptosis. However, PC-3 cells cultured with each
of the compounds, 15e, (R)-15h, and (S)-15h, at 10 μM
showed accumulation in G0/G1, which was not observed for
U937 cells treated with those compounds, and indicates a
diﬀerence in underlying mechanisms in these two cell types. In
contrast, culturing PC-3 cells with Mocetinostat caused an
accumulation of cells in G2/M. When cultured with U937 cells,
Mocetinostat also resulted in the most signiﬁcant increase in
sub-G1 DNA content. Cyclin E expression levels in U937 cells
were lowered upon treatment with all compounds, most
signiﬁcantly with Mocetinostat and (R)-15h; however,
signiﬁcant changes in cyclin E expression levels were not
observed in PC-3 cells using any of the above HDAC inhibitors.
Inhibition of HDAC activity by diﬀerent compounds can cause
changes in cyclin E expression,48,49 but this does not occur in all
cases.50 Diﬀerences in the biological eﬀects among these
compounds could be due to greater isoform selectivity of 15e,
(R)-15h, and (S)-15h compared to that of Mocetinostat,
although that would need to be investigated in a further study.
■ SUMMARY
A new capping group, a chiral oxazoline unit bearing one or
more aryl substituents, has been shown to be eﬀective as a
substructure of N-(2-aminophenyl)-benzamide HDAC inhib-
itors. Inhibition of HDAC1, HDAC2, and HDAC3-NCoR2
(Class I isoforms) was generally potent, with some compounds
in this novel class of inhibitors possessing low nanomolar
potency against HDAC3-NCoR2 that was greater than that of
Mocetinostat, one of the most potent benzamide HDAC
inhibitors previously reported. Highly convergent routes were
established to HDAC inhibitors containing a variety of
enantiopure heterocyclic capping groups by use of a
preassembled N-(2-aminophenyl)-benzamide unit, which is a
new methodology that has been shown to be applicable to the
synthesis of several ﬁve-membered heterocyclic systems linked
by a 2-amino or 2-thio substituent.
To our knowledge, this is the ﬁrst extensive study of the
eﬀect of stereochemistry on HDAC inhibition. These results
show that stereochemistry, both absolute and relative, can be
used to distinguish the aﬃnity of inhibitors to various HDAC
isoforms and that, in some cases, preferential inhibition of an
HDAC isoform can be exhibited by one enantiomer, even when
only one chiral center is present. Further optimization of
HDAC isoform potency and selectivity is likely to be
achievable, and physicochemical data show promise for the
development of new drug-like benzamide HDAC inhibitors.
Such HDAC inhibitors may beneﬁt from the absence of the
commonly required 3-pyridyl terminal capping group and its
metabolism to the N-oxide. This study demonstrates that, at
least in terms of HDAC inhibition, inhibitor solubility, and low
HSA binding, an oxazoline ring can beneﬁcially replace the
pyrimidine ring present in Mocetinostat and, furthermore, that
its pyridine ring can also be replaced, with such inhibitors
leading to restoration of acetylation status in the two cell lines
studied. Thus, each of the compounds, 15e, (S)-15h, (R)-15h,
and Mocetinostat (at 10 μM), increased histone H3K9
acetylation in U937 and PC-3 cell lines. The results of this
study illustrate some advantages of developing new Class I-
selective HDAC inhibitors that incorporate as part of the
capping region a saturated or partly saturated heterocyclic ring
with substituents contributing to a center, or centers, of deﬁned
absolute conﬁguration.
■ EXPERIMENTAL SECTION
Chemistry. All chemicals were used as supplied, except o-
phenylenediamine, which was recrystallized from ethanol. Solvents
used were reagent grade, and anhydrous solvents were obtained from
Anhydrous Engineering (USA) solvent systems after passing through
an alumina column. Compound homogeneity was monitored by
ascending thin-layer chromatography performed on Merck 0.2 mm
aluminum-backed silica gel 60 F254 plates and visualized using an
alkaline potassium permanganate dip or by ultraviolet light. Flash
column chromatography was performed using Merck 0.040 to 0.063
mm, 230 to 400 mesh silica gel. Evaporation refers to the removal of
solvent under reduced pressure. Melting points were determined using
an Electrothermal digital melting point apparatus. Infrared (IR)
spectra were recorded on a PerkinElmer spectrum 100 FT-IR
spectrometer as neat powders or as thin ﬁlms. 1H NMR spectra
were recorded at 300 MHz on a Bruker AMX300 spectrometer, at 400
MHz on a Bruker AMX400, at 500 MHz on a Bruker Avance 500
spectrometer, or at 600 MHz on a Bruker Avance 600 spectrometer in
Figure 2. Analysis of histone H3 acetylation by western blotting. U937
and PC-3 cells were cultured for 24 h with DMSO control or 15e, (S)-
15h, (R)-15h, and Mocetinostat (each at 10 μM), and the expression
of histone H3 and cyclin E as well as the acetylation of histone H3-
lysine 9 (H3K9) was analyzed by western blotting.
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the stated solvent; chemical shifts are reported in δ (ppm) relative to
the internal reference, tetramethylsilane. Mass spectra were obtained
on a Fisons VG70-SE mass spectrometer or Thermo Finnigan
MAT900xp instrument. Purity of tested compounds was assessed to be
at least 95% by LC-MS analysis unless otherwise indicated. For all
samples, 0.1% TFA was added to both eluents.
The following compounds were prepared according to the
literature: 2-amino-2,2-diphenylethanol;51 (S)-2-amino-2-phenylaceta-
mide;52 methyl (S)-2-amino-2-phenylacetate hydrochloride;53 N-(2-
aminophenyl)-4-(chloromethyl)benzamide (1);34 N-Boc-o-phenylene-
diamine;34 (S)-N-((S)-2-((tert-butyldimethylsilyl)oxy)-1-(pyridin-3-
yl)ethyl)-2-methylpropane-2-sulﬁnamide;54 (S)-1-phenylethane-1,2-di-
amine (3);55 (S)-4-phenylimidazolidine-2-thione (4);32 (S)-2-amino-
2-(pyridin-3-yl)ethanol (9c);54 (S)-4-benzyloxazolidine-2-thione
(10a);56 (S)-4-phenyloxazolidine-2-thione (10b);56 (S,E)-N-(2-((tert-
butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulﬁnamide;56
(2S)-2-amino-2-phenylethan-1-ol (12b);36 2-amino-2-(3-
ﬂuorophenyl)ethanol (12c);57 tert-butyl (R)-(2-(4-((3-(2-hydroxy-1-
phenylethyl)thioureido)methyl)benzamido)phenyl)carbamate (S)-
13a;34 tert-butyl (S)-(2-(4-((3-(2-hydroxy-1-phenylethyl)thioureido)-
methyl)benzamido)phenyl)carbamate (S)-13b;34 and N-(2-amino-
phenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide
(Mocetinostat).58
tert-Butyl N-{2-[4-(Isothiocyanatomethyl)benzamido]-
phenyl}carbamate (2). A literature procedure34 was modiﬁed as
follows. Carbon disulﬁde (3.48 mL, 57.5 mmol) was added to a
mixture of 4-(aminomethyl)benzoic acid (3.0 g, 19.8 mmol) and
triethylamine (6.62 mL, 47.5 mmol) in THF (13 mL) and water (13
mL). The mixture was stirred vigorously for 22 h and then cooled to 0
°C, and a solution of iodine (5.38 g, 21.2 mmol) in THF (13 mL) was
added dropwise over 10 min. The mixture was stirred at 0 °C for 2 h;
then, hydrochloric acid (20 mL, 1M) and sodium sulﬁte (0.49 g, 3.9
mmol) were added, and the mixture ws stirred. The mixture was then
extracted with ethyl acetate (100 mL, then 50 mL), and the combined
organic layers were washed with hydrochloric acid (2 × 50 mL, 1M)
and then with brine (50 mL), dried (MgSO4), and evaporated to give
4-(isothiocyanatomethyl)benzoic acid as a cream solid. To a
suspension of the cream solid in dichloromethane (35 mL) was
added oxalyl chloride (2.28 mL, 27.0 mmol) dropwise, followed by a
few drops of DMF. The resulting mixture was stirred at 20 °C for 1 h
(until evolution of gas had ceased), and the resulting solution was
stirred at reﬂux for 1 h. Evaporated gave a residue that was
coevaporated with toluene (20 mL) to ensure complete removal of
oxalyl chloride. The residue was dissolved in dichloromethane (25
mL), and the solution was added dropwise over 10 min to a solution
of N-Boc-o-phenylenediamine34 (3.75 g, 18 mmol) in dichloro-
Figure 3. Analysis of DNA and protein content in PC-3 cells using compounds at 10 μM. Samples were stained with dyes to identify protein and
DNA, followed by ﬂow cytometry. Percentage of cells in G0/G1, S, and G2/M cell cycle phases and with sub-G1 DNA content and low protein
content characteristic of apoptotic cells is shown.
Figure 4. Analysis of DNA and protein content in U937 cells using compounds at 10 μM. Samples were stained with dyes to identify protein and
DNA, followed by ﬂow cytometry. Percentage of cells in G0/G1, S, and G2/M cell cycle phases and with sub-G1 DNA content and low protein
content characteristic of apoptotic cells is shown.
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methane (25 mL) and pyridine (25 mL) at 0 °C. The mixture was
stirred at 0 °C for 1 h, warmed to 20 °C, and stirred for a further 16.5
h. Then aqueous saturated sodium hydrogen carbonate (150 mL) was
added, and the mixture was extracted with chloroform (2 × 100 mL).
The combined organic layers were washed with hydrochloric acid (2 ×
150 mL, 1 M) and then with brine (150 mL), dried over MgSO4, and
evaporated to give an orange oil that was puriﬁed by column
chromatography (3% ethyl acetate/dichloromethane) to give 2 (5.11
g, 74%) as a cream solid. Spectroscopic data were as previously
reported.34
(S)-N-(2-Aminophenyl)-4-(((4-phenyl-4,5-dihydro-1H-imida-
zol-2-yl)thio)methyl)benzamide (5). To a solution of thione 4 (80
mg, 0.45 mmol) and benzyl chloride 1 (117 mg, 0.45 mmol) in
acetone (5 mL) was added potassium carbonate (93 mg, 0.673 mmol).
The mixture was then stirred at reﬂux for 17 h. After allowing the
mixture to cool, the solvent was evaporated, and the residue was
partitioned between water (15 mL) and ethyl acetate (30 mL). The
aqueous layer was extracted with ethyl acetate (2 × 30 mL), and the
combined organic layers were washed with brine (15 mL), dried
(Na2SO4), and evaporated to give a beige solid (200 mg) that was
puriﬁed by column chromatography on silica gel (5:95 methanol/ethyl
acetate) to give a white solid (120 mg, 66%). A small sample was
further puriﬁed by recrystallization from chloroform to give 5 as a
white solid, mp 150−151 °C; [α]D25 −2.1 (c 1.0, methanol); νmax
(cm−1) 3239, 1688, 1642; 1H NMR (600 MHz, chloroform-d) δ ppm
3.58 (1H, br s), 3.86 (2H, br s), 4.12 (1H, br s), 4.39 (1H, d, J = 13.6
Hz), 4.44 (1H, d, J = 13.6 Hz), 4.97 (1H, br s), 6.82−6.89 (2H, m),
7.10 (1H, m), 7.22−7.29 (2H, m), 7.30−7.36 (3H, m), 7.53 (2H, d, J
= 7.9 Hz), 7.81−7.92 (3H, m); 13C NMR (150 MHz, chloroform-d) δ
ppm 35.2, 118.6, 120.0, 124.7, 125.2, 126.4, 127.4, 127.7, 128.8, 129.6,
133.3, 140.7, 141.9, 143.4, 162.8, 165.5; m/z (ESI+) 403 ([M + H]+,
100%); HRMS calcd for C23H23N4OS
+, 403.1587; found, 403.1577.
(S)-tert-Butyl (2-(4-((3-(2-Amino-2-phenylethyl)thioureido)-
methyl)benzamido)phenyl)carbamate (6). To a solution of (S)-
1-phenylethane-1,2-diamine55 (213 mg, 1.56 mmol) in THF (4 mL)
was added a solution of 2 (200 mg, 0.522 mmol) in THF (4 mL). The
resulting solution was stirred at 20 °C for 17.5 h and then evaporated,
and the residue was puriﬁed by ﬂash column chromatography on silica
gel (gradient elution from 1 to 8% of methanolic 2 M ammonia in
dichloromethane) to give 6 (154 mg, 57%) as a white solid, mp 105−
106 °C; νmax (cm
−1) 3276, 1689, 1660; 1H NMR (500 MHz,
chloroform-d) δ ppm 1.47−1.54 (9H, m), 2.32 (4H, br s), 3.50 (1H,
m), 3.76 (1H, br s), 4.12 (1H, dd, J = 8.4, 4.3 Hz), 4.74 (2H, br s),
7.03 (1H, br s), 7.10−7.20 (3H, m), 7.20−7.44 (7H, m), 7.65 (1H,
m), 7.78 (2H, d, J = 7.7 Hz), 9.35 (1H, br s); 13C NMR (125 MHz,
chloroform-d) δ ppm 28.3, 48.0, 51.8, 55.3, 81.5, 124.7, 125.8, 126.2,
126.3, 127.7, 127.7, 127, 128.8, 130.4, 130.5, 132.9, 142.2, 154.7, 165.9,
183.4; m/z (ESI+) 520 ([M + H]+, 100%); HRMS calcd for
C28H34N5O3S
+, 520.2377; found, 520.2365.
(S)-tert-Butyl (2-(4-(((4-Phenyl-4,5-dihydro-1H-imidazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (7). To a sol-
ution of thiourea 6 (154 mg, 0.296 mmol) in acetone (3 mL) was
added iodomethane (0.037 mL, 0.593 mmol), and the solution was
stirred at 20 °C for 18 h. Saturated aqueous sodium hydrogen
carbonate (1.5 mL) was added, and the mixture was stirred for 10 min.
Saturated aqueous sodium hydrogen carbonate (20 mL) and water (5
mL) were added, and the mixture was then extracted with ethyl acetate
(2 × 20 mL). The combined organic layers were dried (Na2SO4) and
evaporated to give 7 (143 mg, 99%) as a cream solid, mp 130−132 °C;
νmax (cm
−1) 3171 (NH), 1667 (CO); 1H NMR (400 MHz,
chloroform-d) δ ppm 1.42 (9H, s, C(CH3)3), 3.35 (1H, t, J = 7.0 Hz),
3.84 (1H, t, J = 8.1 Hz), 4.53 (2H, br s), 4.86 (1H, br s), 7.04 (1H, t, J
= 7.3 Hz), 7.10−7.22 (3H, m), 7.22−7.37 (6H, m), 7.46 (1H, d, J =
7.8 Hz), 7.50 (1H, d, J = 7.6 Hz), 7.69 (1H, br s), 7.86 (2H, d, J = 6.6
Hz), 8.77 (1H, br s), 9.83 (1H, br s); 13C NMR (126 MHz,
chloroform-d) δ ppm 28.3, 46.3, 51.2, 58.7, 81.1, 124.8, 125.1, 126.1,
126.1, 126.4, 127.4, 128.3, 128.7, 129.1, 129.8, 131.5, 133.2, 139.0,
140.0, 154.5, 159.3, 166.2; m/z (ESI+) 486 ([M + H]+, 100%); HRMS
calcd for C28H32N5O3
+, 486.2500; found, 486.2496. (90% purity by
LC-MS and NMR).
(S)-N-(2-Aminophenyl)-4-(((4-phenyl-4,5-dihydro-1H-imida-
zol-2-yl)amino)methyl)benzamide (8). To a solution of 7 (140
mg, 0.288 mmol) in dichloromethane (3 mL) was added triﬂuoro-
acetic acid (0.44 mL, 5.77 mmol) dropwise. The resulting solution was
stirred at 20 °C for 2 h and then evaporated, and the resulting white
solid puriﬁed by MDAP to give 8 (52 mg, 47%) as a white solid, mp
130−133 °C; [α]D25 + 11.1 (c 1.0, methanol); νmax (cm−1) 3217, 1672,
1613; 1H NMR (400 MHz, methanol-d4) δ ppm 3.41 (1H, dd, J = 9.9,
7.2 Hz), 4.02 (1H, t, J = 9.8 Hz), 4.47−4.59 (2H, m), 5.01 (1H, dd, J =
9.5, 7.3 Hz), 6.79 (1H, t, J = 7.3 Hz), 6.93 (1H, dd, J = 8.1, 0.7 Hz),
7.10 (1H, td, J = 7.6, 1.2 Hz), 7.21 (1H, d, J = 7.6 Hz), 7.26−7.41 (5H,
m), 7.53 (2H, d, J = 8.2 Hz), 8.01 (2H, d, J = 8.2 Hz); 13C NMR (100
MHz, methanol-d4) δ ppm 45.7, 54.0, 61.3, 117.4, 118.3, 123.9, 125.9,
126.3, 127.0, 127.2, 127.5, 127.8, 128.4, 133.2, 142.4, 142.6, 161.3,
167.2; m/z (ESI+) 386 ([M + H]+, 100%); HRMS calcd for
C23H24N5O
+, 386.1975; found, 386.1974.
(S)-4-(Pyridin-3-yl)oxazolidine-2-thione (10c). To a ﬂask
located behind a blast shield that contained a stirred mixture of
amino alcohol 9c (160 mg, 1.19 mmol), potassium carbonate (80 mg,
0.58 mmol), and carbon disulﬁde (0.14 mL, 2.32 mmol) in ethanol (1
mL) at 50 °C was added dropwise hydrogen peroxide (0.15 mL, 1.72
mmol) (Caution: Exothermic!). After completing the addition, the
mixture was cooled to 20 °C and ﬁltered. The ﬁltrate was diluted with
ethyl acetate (30 mL), washed with water (2 × 15 mL), aqueous
sodium sulﬁte (10%, 15 mL), and brine, dried (Na2SO4), and
evaporated. The yellow solid was puriﬁed by ﬂash column
chromatography on silica gel (0−5% of 2 M ammonia/methanol in
dichloromethane) to give 10c (29 mg, 14%) as a white solid, mp 157−
159 °C; νmax (cm
−1) 3083; 1H NMR (400 MHz, methanol-d4) δ ppm
4.52 (1H, dd, J = 9.2, 6.2 Hz), 5.04 (1H, t, J = 9.2 Hz), 5.28 (1H, dd, J
= 9.2, 6.2 Hz), 7.53 (1H, dd, J = 7.8, 4.9 Hz), 7.87 (1H, d, J = 7.8 Hz),
8.49−8.63 (2H, m); 13C NMR (100 MHz, methanol-d4) δ ppm 57.6,
76.8, 124.4, 134.8, 136.0, 147.2, 149.1, 190.2; m/z (ESI+) 181 ([M +
H]+, 100%); HRMS calcd for C8H9N2S
+, 181.0436; found, 181.0430.
(S)-N-(2-Aminophenyl)-4-(((4-benzyl-4,5-dihydrooxazol-2-
yl)thio)methyl)benzamide (11a). To a solution of thione 10a (84
mg, 0.44 mmol) and benzyl chloride 1 (95 mg, 0.36 mmol) in acetone
(4 mL) was added potassium carbonate (75 mg, 0.543 mmol). The
mixture was then stirred at reﬂux for 16.5 h and then evaporated. The
residue was partitioned between water (15 mL) and ethyl acetate (20
mL), and the layers were then separated. The aqueous layer was
extracted with ethyl acetate (15 mL), and the combined organic layers
were washed with brine, dried (MgSO4), and evaporated to give a solid
that was puriﬁed by column chromatography on silica gel (1:1 ethyl
acetate/hexane) to give 11a (106 mg, 70%) as a cream solid, mp 137−
140 °C; [α]D
25 −32.0 (c 0.5, methanol); νmax (cm−1) 3274, 1649; 1H
NMR (300 MHz, chloroform-d) δ ppm 2.66 (1H, dd, J = 13.8, 8.3
Hz), 3.08 (1H, dd, J = 13.8, 5.5 Hz), 3.86 (2H, br s), 4.03−4.12 (1H,
m), 4.19−4.35 (3H, m), 4.43 (1H, m), 6.75−6.89 (2H, m), 7.07 (1H,
m), 7.14−7.35 (6H, m,), 7.48 (2H, d, J = 8.0 Hz, H(11 and 13)), 7.83
(2H, d, J = 8.0 Hz), 7.96 (1H, br s); 13C NMR (125 MHz, chloroform-
d) δ ppm 36.2, 42.0, 68.2, 74.0, 118.8, 120.2, 125.0, 125.6, 127.0,
127.7, 128.0, 129.0, 129.6, 129.8, 133.7, 138.0, 141.1, 141.7, 165.3,
165.8; m/z (ESI−) 416 ([M − H]−, 100%); HRMS calcd for
C24H22N3O2S
−, 416.1438; found, 416.1433.
(S)-N-(2-Aminophenyl)-4-(((4-phenyl-4,5-dihydrooxazol-2-
yl)thio)methyl)benzamide (11b). To a solution of thione 10b (185
mg, 1.03 mmol) and benzyl chloride 1 (269 mg, 1.03 mmol) in
acetone (10 mL) was added potassium carbonate (213 mg, 1.56
mmol). The mixture was stirred at reﬂux for 18 h and then evaporated.
The residue was partitioned between water (40 mL) and ethyl acetate
(40 mL). The organic layer was washed with brine, dried (MgSO4),
and evaporated to give a solid that was puriﬁed by column
chromatography on silica gel (ethyl acetate/hexane, 1:1) and was
then puriﬁed again by column chromatography on silica gel
(dichloromethane/ethyl acetate, 4:1 to 3:1) to give 11b as a cream
solid (66 mg, 16%), mp 64−65 °C; [α]D25 −14.0 (c 0.5, methanol); νmax
(cm−1) 3292, 1653; 1H NMR (400 MHz, chloroform-d) δ ppm 3.91
(2H, br s), 4.22 (1H, t, J = 8.0 Hz), 4.31−4.46 (2H, m), 4.75 (1H, t, J
= 8.9 Hz), 5.25 (6H, dd, J = 9.5, 8.0 Hz), 6.83−6.93 (2H, m, H), 7.13
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(1H, t, J = 7.3 Hz), 7.21 (2H, d, J = 7.0 Hz), 7.26−7.41 (6H, m), 7.56
(2H, d, J = 8.0 Hz), 7.87 (3H, d, J = 7.5 Hz); 13C NMR (125 MHz,
chloroform-d) δ ppm 35.9, 69.9, 76.6, 118.5, 119.8, 124.6, 125.4, 126.6,
127.4, 127.7, 127.9, 128.8, 129.5, 133.4, 140.8, 141.4, 141.9, 165.6,
166.0; m/z (CI) 404 ([M + H]+, 100%); HRMS calcd for
C23H22N3O2S
+, 404.1427; found, 404.1426; 66% purity by LC-MS.
(S)-N-(2-Aminophenyl)-4-(((4-(pyridin-3-yl)-4,5-dihydrooxa-
zol-2-yl)thio)methyl)benzamide (11c). To a solution of amino
alcohol 10c (25 mg, 0.139 mmol) and the arylmethyl chloride 1 (36.2
mg, 0.139 mmol) in acetone (2 mL) was added potassium carbonate
(28.8 mg, 0.208 mmol), and the mixture was stirred at reﬂux for 17 h.
Since the volume had decreased, acetone (3 mL) was added, and then
mixture was then stirred at reﬂux for 6 h. After allowing the mixture to
cool, the mixture was partitioned between water (15 mL) and ethyl
acetate (20 mL), and the layers then separated. The aqueous layer was
extracted with ethyl acetate (15 mL), and the combined organic layers
were dried (Na2SO4) and evaporated to give a solid that was puriﬁed
by MDAP to give 11c (25 mg, 45%) as a white solid, mp 107−110 °C;
[α]D
25 + 22.0 (c 0.25, methanol); νmax (cm
−1) 3212, 1645; 1H NMR
(500 MHz, methanol-d4) δ ppm 4.23 (1H, t, J = 8.0 Hz), 4.38 (1H, d, J
= 13.7 Hz), 4.44 (1H, d, J = 13.7 Hz), 4.83 (1H, t, J = 9.3 Hz), 5.35
(1H, dd, J = 9.3, 7.7 Hz), 6.80 (1H, t, J = 7.4 Hz), 6.93 (1H, d, J = 8.0
Hz), 7.11 (1H, t, J = 7.4 Hz), 7.22 (1H, d, J = 7.7 Hz), 7.43 (1H, dd, J
= 7.7, 4.9 Hz), 7.60 (3H, d, J = 8.0 Hz), 7.96 (2H, d, J = 8.0 Hz), 8.40
(1H, s), 8.49 (1H, d, J = 4.7 Hz); 13C NMR (125 MHz, methanol-d4)
δ ppm 34.8, 67.1, 75.9, 117.3, 118.3, 123.9, 124.1, 126.3, 127.2, 127.7,
128.4, 133.4, 135.1, 138.3, 141.5, 142.4, 147.2, 148.0, 167.1, 167.7; m/z
(ESI+) 405 ([M + H]+, 100%); HRMS calcd for C22H21N4O2S
+,
405.1380; found, 405.1384; 93% purity by LC-MS.
2-Amino-2-(4-ﬂuorophenyl)ethan-1-ol (12d). A three-necked
ﬂask was ﬁtted with a magnetic stirrer and a reﬂux condenser and then
ﬂame-dried. Under an atmosphere of nitrogen, sodium borohydride
(0.224 g, 5.92 mmol) was added, followed by anhydrous THF (10
mL). Then, a dropping funnel was ﬁtted, and the mixture was cooled
in an ice bath to 0 °C. A solution of iodine (1.05 g, 2.96 mmol) in
THF (10 mL) was added dropwise over 30 min. After the vigorous
evolution of gas had ceased, 4-ﬂuoro-DL-phenylglycine (0.50 g, 2.96
mmol) was added, and the mixture was heated at reﬂux for 17 h. After
allowing the mixture to cool, methanol was added slowly until the
solution became clear. The mixture was stirred for 30 min, and then
the solvent was evaporated. The resulting white paste was dissolved in
aqueous potassium hydroxide (20%, 30 mL). After stirring it for 6 h,
the mixture was extracted with dichloromethane (3 × 30 mL). The
combined organic layers were washed with brine (20 mL then 75 mL),
dried (Na2SO4), and evaporated to give crude 12d as a white solid that
was used without further puriﬁcation (0.22 g, 48%); 1H NMR (400
MHz, chloroform-d) δ ppm 2.51 (3H, br s), 3.54 (1H, dd, J = 10.8, 8.3
Hz), 3.72 (1H, dd, J = 10.8, 4.3 Hz), 4.07 (1H, dd, J = 8.3, 4.3 Hz),
7.05 (2H, t, J = 8.8 Hz), 7.32 (2H, dd, J = 8.5, 5.5 Hz).
2-Amino-2-(4-(triﬂuoromethyl)phenyl)ethanol (12f). To a
suspension of 2-amino-2-(4-(triﬂuoromethyl)phenyl)acetic acid (1.50
g, 6.84 mmol) in anhydrous THF (15 mL) at 20 °C was added
borane−THF complex (1 M in THF, 17.1 mL) dropwise over 5 min;
then, the solution was stirred at 70 °C for 16.5 h. After cooling the
mixture to 20 °C, methanol (10 mL) was added cautiously, and the
mixture was then stirred for 30 min. The solvent was evaporated, and
the resulting yellow paste was stirred with potassium hydroxide (20%
aq w/w, 30 mL) for 4 h at 20 °C. The mixture was then extracted with
ethyl acetate (3 × 30 mL), and the combined organic layers were
washed with brine, dried (Na2SO4), and evaporated to give a yellow
semisolid (1.3 g). Puriﬁcation by ﬂash column chromatography on
silica gel (2−10% of 2 M ammonia/methanol in dichloromethane)
gave 12f (0.646 g, 46%) as a white solid, mp 110−116 °C; 1H NMR
(500 MHz, chloroform-d) δ ppm 2.14 (3H, br s), 3.58 (1H, dd, J =
10.7, 8.0 Hz), 3.78 (1H, dd, J = 10.7, 4.1 Hz), 4.16 (1H, dd, J = 8.0, 4.1
Hz), 7.49 (2H, d, J = 8.1 Hz), 7.63 (2H, d, J = 8.1 Hz); 13C NMR (125
MHz, chloroform-d) δ ppm 57.0 (s), 67.8 (s), 124.1 (q, J = 271.9 Hz),
125.5 (q, J = 3.7 Hz), 126.9 (s), 129.8 (q, J = 32.5 Hz), 146.6 (s); m/z
(ESI+) 206 ([M + H]+, 100%); HRMS calcd for C9H11NOF3
+,
206.0787; found, 206.0790.
(R)-4-(1-Amino-2-hydroxyethyl)phenol (12g). To a suspension
of (R)-2-amino-2-(4-hydroxyphenyl)acetic acid (1.0 g, 5.98 mmol) in
anhydrous THF (10 mL) at 20 °C was added borane−THF complex
in THF (20 mL, 1M) dropwise over 5 min; then, the solution was
stirred at 70 °C for 44 h. After cooling the mixture to 20 °C, methanol
(10 mL) was added cautiously, and the mixture was stirred for 30 min.
The solvent was then evaporated, and the resulting white paste was
stirred with potassium hydroxide (20% aqueous w/w, 20 mL) for 4 h
at 20 °C. The solution was neutralized to pH 7 with hydrochloric acid
(2M) and then washed with ethyl acetate (20 mL). The aqueous layer
was evaporated, and the resulting white solid was stirred for 1 h with
1:4 ethanol/chloroform (50 mL), ﬁltered, and evaporated to give 12g
(300 mg, 33%) as a colorless oil that was used without further
puriﬁcation.
Preparation of Yellow Mercuric Oxide. To a solution of
mercury(II) chloride (1.0 g, Caution: TOXIC!) in water (22 mL) was
added a sirred solution of sodium hydroxide (0.60 g) in water (8 mL).
The mixture was stirred at 20 °C for 5 min. The precipitate was
ﬁltered and dried under vacuum overnight over phosphorus pentoxide
to give mercuric oxide as a yellow solid (0.58 g).
tert-Butyl (S)-(2-(4-(((4-Benzyl-4,5-dihydrooxazol-2-yl)-
amino)methyl)benzamido)phenyl)carbamate (14a). To a sol-
ution of tert-butyl (R)-(2-(4-((3-(2-hydroxy-1-phenylethyl)-
thioureido)methyl)benzamido)phenyl)carbamate (S)-13a34 (0.524 g,
0.98 mmol) in ethanol (7 mL) and toluene (14 mL) was added freshly
prepared yellow mercuric oxide (0.58 g, 2.6 mmol); the resulting
mixture was stirred at reﬂux for 30 min. After cooling the mixture to 20
°C, it was ﬁltered through Celite, and the ﬁltrate was evaporated to
give 14a as a white solid (0.45 g, 92%), mp 200−201 °C; νmax (cm−1)
3308, 1664, 1650; 1H NMR (500 MHz, chloroform-d) δ ppm 1.51
(9H, s), 2.66 (1H, dd, J = 13.5, 8.5 Hz), 3.06 (1H, dd, J = 13.5, 4.7
Hz), 4.03 (1H, t, J = 7.1 Hz), 4.22 (1H, t, J = 8.2 Hz), 4.32 (1H, m),
4.43 (1H, d, J = 15.3 Hz), 4.47 (1H, d, J = 15.3 Hz), 6.93 (1H, br s),
7.13−7.32 (5H, m), 7.38 (2H, d, J = 7.9 Hz), 7.79 (1H, d, J = 7.7 Hz),
7.92 (2H, d, J = 7.9 Hz), 9.19 (1H, br s); 13C NMR (125 MHz,
chloroform-d) δ ppm 28.4, 42.4, 46.7, 65.1, 72.5, 81.5, 124.6, 125.8,
126.0, 126.1, 126.5, 127.4, 127.8, 128.6, 129.3, 130.0, 131.0, 133.5,
138.0, 142.9, 154.7, 160.8, 165.4; m/z (ESI−) 499 ([M − H]−, 100%);
HRMS calcd for C29H31N4O4
−, 499.2351; found, 499.2358.
(S)-(tert-Butyl 2-(4-(((4-Phenyl-4,5-dihydrooxazol-2-yl)-
amino)methyl)benzamido)phenyl)carbamate (S)-(14b). To a
solution of tert-butyl (S)-2-(2-(4-((3-(2-hydroxy-1-phenylethyl)-
thioureido)methyl)benzamido)phenyl)carbamate (S)-13b34 (180 mg,
0.345 mmol) in ethanol (3.5 mL) and toluene (7 mL) was added
yellow mercuric oxide (375 mg, 1.73 mmol) in portions. The resulting
mixture was stirred at reﬂux for 2 h. The cool mixture was ﬁltered
through Celite, and the ﬁltrate was evaporated. The residue was
dissolved in ethanol (3.5 mL) and toluene (7 mL); then, yellow
mercuric oxide (375 mg, 1.73 mmol) was added, and the mixture
stirred at reﬂux for 4 h. When it was cool, the mixture was ﬁltered
through Celite, yellow mercuric oxide (375 mg, 1.73 mmol) was
added, and the mixture was stirred at reﬂux for 4 h. Filtration of the
mixture through Celite and evaporation of the ﬁltrate aﬀorded (S)-14b
as a foamy white solid (0.127 g, 76%), mp 100−103 °C; νmax (cm−1)
3274, 1654; 1H NMR (400 MHz, chloroform-d) δ ppm 1.51 (9H, s),
4.11 (1H, t, J = 7.5 Hz), 4.47 (2H, s), 4.66 (1H, t, J = 8.5 Hz), 5.12
(1H, dd, J = 9.0, 7.3 Hz), 7.15 (1H, td, J = 7.5, 1.6 Hz), 7.19 (1H, td, J
= 7.5, 1.6 Hz), 7.24−7.30 (5H, m), 7.31−7.39 (4H, m), 7.73 (1H, d, J
= 7.3 Hz), 7.89 (2H, d, J = 8.0 Hz), 9.33 (1H, br s); 13C NMR (125
MHz, chloroform-d) δ ppm 28.7), 47.0, 67.8, 75.8, 81.6, 124.9, 126.1,
126.2, 126.3, 126.8, 127.7, 127.9, 128.1, 129.0, 130.5, 131.2, 133.6,
143.3, 143.8, 155.0, 162.0, 165.9; m/z (ESI−) 485 ([M − H]−, 95%);
HRMS calcd for C28H29N4O4
−, 485.2194; found, 485.2206.
(R)-tert-Butyl 2-(4-(((4-Phenyl-4,5-dihydrooxazol-2-yl)-
amino)methyl)benzamido)phenyl)carbamate (R)-(14b). To a
solution of (R)-phenylalaninol (110 mg, 0.80 mmol) in THF (12 mL)
was added isothiocyanate 2 (337 mg, 0.88 mmol), and the mixture was
stirred at 20 °C for 18 h. Evaporation gave a residue that was dissolved
in acetone (6 mL); iodomethane (0.10 mL, 1.6 mmol) was added, and
the solution was stirred at 20 °C for 9 h. Saturated aqueous sodium
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hydrogen carbonate (2 mL) was then added, and the mixture was
stirred for 10 min. Saturated aqueous sodium hydrogen carbonate (20
mL) was then added, and the mixture was extracted with ethyl acetate
(2 × 20 mL). The combined organic layers were washed with brine
(20 mL), dried (Na2SO4), and evaporated to give a white solid that
was puriﬁed by column chromatography on silica gel (5:95 methanol/
ethyl acetate) to give (R)-14b (159 mg, 41%) as a white solid, mp
104−106 °C; νmax (cm−1) 3277, 1653; 1H NMR (300 MHz,
chloroform-d) δ ppm 1.48 (9H, s), 4.08 (1H, t, J = 7.5 Hz), 4.44
(2H, s), 4.63 (1H, t, J = 8.6 Hz), 5.09 (1H, dd, J = 8.9, 7.3 Hz), 7.03−
7.39 (13H, m), 7.70 (1H, m), 7.85 (2H, d, J = 8.1 Hz), 9.30 (1H, br
s); 13C NMR (75 MHz, chloroform-d) δ ppm 28.4, 46.7, 67.6, 75.6,
81.3, 124.7, 125.8, 125.9, 126.1, 126.6, 127.4, 127.6, 127.9, 128.8,
130.3, 130.9, 133.3, 143.1, 143.6, 154.8, 161.8, 165.7; m/z (ESI+) 487
([M + H]+, 100%); HRMS calcd for C28H31N4O4
+, 487.2340; found,
487.2336.
(S)-tert-Butyl (2-(4-(((4-(Pyridin-3-yl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (14c). To a
solution of 9c (155 mg, 1.12 mmol) in THF (8 mL) and methanol
(3 mL) was added isothiocyanate 2 (330 mg, 0.86 mmol), and the
mixture was stirred at 20 °C for 17 h. Evaporation gave a residue that
was dissolved in acetone (4 mL); iodomethane (0.108 mL, 1.72
mmol) was then added, and the solution was stirred at 20 °C for 5 h.
The solution was then worked up as described for (R)-14b to give a
solid that was puriﬁed by ﬂash column chromatography on silica gel
(gradient elution from 2 to 10% of methanolic 2 M ammonia in
dichloromethane) to give 14c (86 mg, 21%) as a white solid, mp 107−
108 °C; νmax (cm
−1) 3265, 1651; 1H NMR (400 MHz, chloroform-d)
δ ppm 1.50 (9H, s), 4.06 (1H, dd, J = 7.8, 7.2 Hz), 4.48 (2H, s), 4.66
(1H, dd, J = 7.8, 7.0), 5.12 (1H, dd, J = 8.7, 7.2 Hz), 5.43 (1H, br s),
7.09−7.22 (2H, m), 7.26 (1H, m), 7.30−7.42 (4H, m), 7.56 (1H, d, J
= 7.8 Hz), 7.73 (1H, d, J = 6.8 Hz), 7.88 (2H, d, J = 7.8 Hz), 8.42 (1H,
s), 8.49 (1H, d, J = 3.7 Hz), 9.39 (1H, br s); 13C NMR (100 MHz,
chloroform-d) δ ppm 28.3, 46.6, 65.5, 74.9, 81.1, 123.6, 124.5, 125.6,
125.7, 126.0, 127.4, 127.8, 130.3, 130.7, 133.5, 134.2, 139.2, 142.6,
148.2, 148.7, 154.6, 162.0, 165.7; m/z (ESI+) 488 ([M + H]+, 100%);
HRMS calcd for C27H30N5O4
+, 488.2292; found, 488.2285.
tert-Butyl (2-(4-(((4-(4-Fluorophenyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (14d). To a
solution of amino alcohol 12d (220 mg, 1.42 mmol) in THF (10
mL) was added isothiocyanate 2 (272 mg, 0.71 mmol); the resulting
solution was stirred at 20 °C for 18 h. The solvent was evaporated, and
the residue was dissolved in acetone (5 mL); iodomethane (0.09 mL,
1.45 mmol) was then added, and the solution stirred at 20 °C for 16 h.
The solution was then worked up as described for (R)-14b to give a
solid that was puriﬁed by column chromatography on silica gel (4:1
ethyl acetate/hexane) to give 14d (238 mg, 67%) as a white solid, mp
105−108 °C; νmax (cm−1) 3258, 1650; 1H NMR (400 MHz,
chloroform-d) δ ppm 1.51 (9H, s), 4.06 (1H, t, J = 7.7 Hz), 4.50
(2H, s), 4.65 (1H, t, J = 8.5 Hz), 5.11 (1H, dd, J = 8.9, 7.4 Hz), 7.02
(2H, t, J = 8.7 Hz), 7.12−7.30 (6H, m), 7.39 (2H, d, J = 8.0 Hz), 7.77
(1H, d, J = 7.5 Hz), 7.91 (2H, d, J = 8.0 Hz), 9.32 (1H, br s); 13C
NMR (125 MHz, chloroform-d) δ ppm 28.3, 46.6, 66.8, 75.4, 81.3,
115.4 (d, J = 22.1 Hz), 124.5, 125.7, 125.9, 127.3, 127.7, 128.0 (d, J =
8.6 Hz), 130.0, 130.8, 133.3, 139.2, 142.7, 154.6, 162.1 (d, J = 244.7
Hz), 161.5, 165.3; m/z (CI) 505 ([M + H]+, 93%); HRMS calcd for
C28H30FN4O4
+, 505.2246; found, 505.2254.
tert-Butyl (2-(4-(((4-(3-Fluorophenyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (14e). To a
solution of 12e (81 mg, 0.522 mmol) in THF (6 mL) was added
isothiocyanate 2 (200 mg, 0.522 mmol), and the resulting solution was
stirred at 20 °C for 16 h. Evaporation gave a residue that was dissolved
in acetone (3 mL); iodomethane (0.10 mL, 1.56 mmol) was then
added, and the solution was stirred at 20 °C for 4 h. The solution was
then worked up as described for (R)-14b to give a solid that was
puriﬁed by ﬂash column chromatography on silica gel (75−100% ethyl
acetate/cyclohexane) to give 14e (200 mg, 76%) as a white solid, mp
104−107 °C; νmax (cm−1) 3283, 1652; 1H NMR (400 MHz,
chloroform-d) δ ppm 1.51 (1H, s), 3.95 (1H, br s), 4.07 (1H, dd, J
= 8.1, 7.1 Hz), 4.44−4.54 (2H, m), 4.64 (1H, dd, J = 9.0, 8.1 Hz), 5.11
(1H, dd, J = 9.0, 7.1 Hz), 6.91−7.04 (3H, m), 7.11−7.21 (2H, m)),
7.22−7.32 (3H, m), 7.36 (2H, d, J = 8.3 Hz), 7.73 (1H, dd, J = 7.8, 1.2
Hz), 7.89 (2H, d, J = 8.3 Hz), 9.28 (1H, br s); 13C NMR (100 MHz,
chloroform-d) δ ppm 28.3, 46.6, 67.0, 75.2, 81.2, 113.3 (d, J = 22.0
Hz), 114.3 (d, J = 21.3 Hz), 122.0 (d, J = 2.2 Hz), 124.5, 125.7, 125.8,
125.9, 127.3, 127.8, 130.1 (d, J = 8.1 Hz), 130.2, 130.8, 133.3, 142.7,
146.3 (d, J = 6.6 Hz), 154.6, 161.8, 163.1 (d, J = 245.8 Hz), 165.5; m/z
(ESI+) 505 ([M + H]+, 100%); HRMS calcd for C28H30FN4O4
+,
505.2246; found, 505.2240.
tert-Butyl (2-(4-(((4-(4-(Triﬂuoromethyl)phenyl)-4,5-dihy-
drooxazol-2-yl)amino)methyl)benzamido)phenyl)carbamate
(14f). To a solution of 12f (107 mg, 0.522 mmol) in THF (6 mL) was
added 2 (200 mg, 0.522 mmol). The mixture was stirred at 20 °C for
17.5 h. Evaporation gave a residue that was dissolved in acetone (3
mL); iodomethane (0.065 mL, 1.04 mmol) was added, and the
solution was stirred at 20 °C for 6 h. A further 65 μL of iodomethane
was then added, and the mixture stirred for another 2.5 h at 20 °C.
The mixture was worked up as described for (R)-14b to give a solid
that was puriﬁed by ﬂash column chromatography on silica gel
(gradient elution from 1 to 5% of methanolic 2 M ammonia in
dichloromethane) to give 14f (200 mg, 69%) as a white solid, mp
114−116 °C; νmax (cm−1) 3282, 1658; 1H NMR (400 MHz,
chloroform-d) δ ppm 1.49 (9H, s), 4.04 (1H, t, J = 7.6 Hz), 4.44
(2H, s), 4.65 (1H, t, J = 8.7 Hz), 4.94 (1H, br s), 5.14 (1H, t, J = 8.1
Hz), 7.05−7.18 (2H, m), 7.24 (1H, dd, J = 7.6, 1.2 Hz), 7.31 (2H, d, J
= 8.1 Hz), 7.36 (2H, d, J = 8.1 Hz), 7.47 (1H, br s), 7.57 (2H, d, J =
8.1 Hz), 7.70 (1H, d, J = 7.1 Hz), 7.85 (2H, d, J = 8.1 Hz), 9.39 (1H,
br s); 13C NMR (100 MHz, chloroform-d) δ ppm 28.3, 46.5, 67.0,
75.0, 81.1, 124.1 (q, J = 272.9 Hz), 124.5, 125.5 (q, J = 3.7 Hz), 125.6,
125.9, 126.8, 127.2, 127.7, 129.6 (q, J = 32.3 Hz), 130.3, 130.7, 133.2,
142.8, 147.6, 154.7, 162.1, 165.6; m/z (ESI+) 387 ([M + H]+, 100%);
HRMS calcd for C29H30N4O4F3
+, 555.2214; found, 555.2214.
(S)-tert-Butyl (2-(4-(((4-(4-Hydroxyphenyl)-4,5-dihydrooxa-
zol-2-yl)amino)methyl)benzamido)phenyl)carbamate (14g).
To a solution of thiourea 13g29 (270 mg, 0.503 mmol) in acetone
(4 mL) was added iodomethane (0.045 mL, 0.75 mmol); the solution
was then stirred at 20 °C for 4 h. More iodomethane (0.045 mL, 0.75
mmol) was then added, followed by stirring at 20 °C for an additional
17.5 h. The mixture was worked up as described for (R)-14b to give
14g (250 mg, 99%) as a white solid, mp 133−139 °C; νmax (cm−1)
3282, 1650; 1H NMR (400 MHz, chloroform-d) δ ppm 1.49 (9H, s),
4.09 (1H, t, J = 7.5 Hz), 4.33−4.50 (2H, m), 4.48 (1H, br s), (4.58
(1H, t, J = 8.6 Hz), 4.98 (1H, dd, J = 8.8, 7.1 Hz), 6.58 (2H, d, J = 8.5
Hz), 6.91 (2H, d, J = 8.5 Hz), 7.11−7.21 (2H, m), 7.27−7.35 (4H, m),
7.68 (1H, m), 7.83 (2H, d, J = 8.3 Hz), 9.37 (1H, br s); 13C NMR
(125 MHz, chloroform-d) δ ppm 28.3, 46.3, 66.2, 75.7, 81.3, 115.9,
124.6, 125.6, 125.7, 126.1, 127.2, 127.5, 127.4, 130.4, 130.6, 132.9,
133.6, 142.7, 154.6, 156.3, 161.5, 165.8; m/z (ESI+) 503 ([M + H]+,
100%); HRMS calcd for C28H31N4O5
+, 503.2289; found, 503.2281.
(R)-tert-Butyl (2-(4-(((5-Phenyl-4,5-dihydrooxazol-2-yl)-
amino)methyl)benzamido)phenyl)carbamate (R)-(14h). To a
solution of (R)-2-amino-1-phenylethanol (110 mg, 0.80 mmol) in
THF (8 mL) was added isothiocyanate 2 (307 mg, 0.8 mmol); the
mixture was stirred at 20 °C for 18 h. Evaporation gave a residue that
was dissolved in acetone (4 mL); iodomethane (0.10 mL, 1.60 mmol)
was then added, and the mixture was stirred at 20 °C for 6 h. Saturated
aqueous sodium hydrogen carbonate (2 mL) was added, and the
mixture stirred for 10 min, diluted with saturated aqueous sodium
hydrogen carbonate (20 mL), and extracted with ethyl acetate (2 × 20
mL). The combined organic layers were dried (Na2SO4) and
evaporated to give a yellow oil that was puriﬁed by ﬂash column
chromatography on silica gel (gradient elution from 1 to 5% of
methanolic 2 M ammonia in dichloromethane) to give (R)-14h (291
mg, 75%) as a white solid, mp 97−99 °C; νmax (cm−1) 3277, 1659; 1H
NMR (400 MHz, chloroform-d) δ ppm 1.48 (9H, s), 3.67 (1H, dd, J =
12.2, 7.3 Hz), 4.14 (1H, dd, J = 12.2, 9.2 Hz), 4.41 (2H, s), 5.02 (1H,
br s), 5.49 (1H, t, J = 8.3 Hz), 7.04−7.19 (2H, m), 7.22−7.48 (9H, m),
7.65 (1H, m), 7.84 (2H, d, J = 8.3 Hz), 9.48 (1H, br s); 13C NMR
(100 MHz, chloroform-d) δ ppm 28.3, 46.4, 60.1, 80.9, 81.7, 124.5,
125.4, 125.6, 125.7, 125.9, 127.1, 127.8, 128.4, 128.8, 130.5, 130.6,
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133.1, 140.3, 142.8, 154.7, 160.8, 165.7; m/z (ESI+) 487 ([M + H]+,
100%); HRMS calcd for C28H31N4O4
+, 487.2340; found, 487.2342.
(S)-tert-Butyl (2-(4-(((5-Phenyl-4,5-dihydrooxazol-2-yl)-
amino)methyl)benzamido)phenyl)carbamate (S)-(14h). To a
solution of (S)-2-amino-1-phenylethanol (110 mg, 0.8 mmol) in
THF (8 mL) was added isothiocyanate 2 (307 mg, 0.80 mmol); the
mixture was stirred at 20 °C for 18 h. Evaporation gave a residue that
was dissolved in acetone (4 mL); iodomethane (0.10 mL, 1.6 mmol)
was then added, and the solution was stirred at 20 °C for 4 h. The
mixture was worked up as described for (S)-14h to give a solid that
was puriﬁed by ﬂash column chromatography on silica gel (gradient
elution from 1 to 5% of methanolic 2 M ammonia in dichloro-
methane) to give (S)-14h (275 mg, 71%) as a white solid, mp 100−
102 °C; νmax (cm
−1) 3274 (NH), 1655 (CO); 1H NMR (400 MHz,
chloroform-d) δ ppm 1.51 (9H, s), 3.73 (1H, dd, J = 12.2, 7.3 Hz),
4.20 (1H, dd, J = 12.3, 9.2 Hz), 4.49 (2H, s), 5.52 (1H, dd, J = 9.2, 7.3
Hz), 7.12−7.23 (2H, m), 7.27−7.43 (9H, m), 7.75 (1H, d, J = 7.6 Hz),
7.91 (2H, d, J = 8.1 Hz), 9.31 (1H, br s); 13C NMR (100 MHz,
chloroform-d) δ ppm 28.3, 46.6, 60.7, 81.2, 81.7, 124.5, 125.6, 125.7,
125.8, 125.9, 127.3, 127.8, 128.3, 128.8, 130.2, 130.8, 133.3, 140.5,
142.9, 154.6, 160.5, 165.5; m/z (ESI+) 487 ([M + H]+, 100%); HRMS
calcd for C28H31N4O4
+, 487.2340; found, 487.2327.
tert-Butyl (2-(4-(((4,4-Diphenyl-4,5-dihydrooxazol-2-yl)-
amino)methyl)benzamido)phenyl)carbamate (14i). To a sol-
ution of 2-amino-2,2-diphenylethanol (122 mg, 0.574 mmol) in THF
(6 mL) was added 2 (200 mg, 0.522 mmol), and the resulting solution
was stirred at 20 °C for 24 h and then at reﬂux for 18 h. Evaporation of
the solvent gave a residue that was dissolved in acetone (3 mL);
iodomethane (0.098 mL, 1.565 mmol) was then added, and the
solution was stirred at 20 °C for 4 h. The mixture was worked up as
described for (R)-14h to give a solid that was puriﬁed by ﬂash column
chromatography on silica gel (gradient elution from 1 to 5% of
methanolic 2 M ammonia in dichloromethane) to give 14i (290 mg,
99%) as a white solid, mp 104−106 °C; νmax (cm−1) 3276, 1658; 1H
NMR (400 MHz, chloroform-d) δ ppm 1.50 (9H, s), 4.49 (2H, s),
4.80 (2H, s), 7.08−7.39 (16H, m), 7.72 (1H, d, J = 6.8 Hz), 7.87 (2H,
d, J = 8.3 Hz), 9.26 (1H, br s); 13C NMR (100 MHz, chloroform-d) δ
ppm 28.3, 46.5, 80.0, 81.2, 124.6, 125.7, 125.8, 126.0, 126.6, 126.9,
127.4, 127.7, 128.3, 130.2, 130.8, 133.1, 143.3, 146.9, 154.7, 160.1,
165.6; m/z (ESI+) 563 ([M + H]+, 100%); HRMS calcd for
C34H35N4O4
+, 563.2653; found, 563.2639.
tert-Butyl (2-(4-((((4S,5S)-4,5-Diphenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (14j). To a
solution of (1S,2S)-2-amino-1,2-diphenylethanol (122 mg, 0.574
mmol) in THF (6 mL) was added isothiocyanate 2 (200 mg, 0.522
mmol); the mixture was then stirred at 20 °C for 16 h. Evaporation
gave a residue that was dissolved in acetone (3 mL); iodomethane
(0.01 mL, 1.56 mmol) was then added, and the solution was stirred at
20 °C for 5.5 h. The mixture was worked up as described for (R)-14h
to give a solid that was puriﬁed by ﬂash column chromatography on
silica gel (gradient elution from 1 to 5% of methanolic 2 M ammonia
in dichloromethane) to give 14j (165 mg, 56%) as a white solid, mp
137−139 °C; νmax (cm−1) 3271, 1656; 1H NMR (400 MHz,
chloroform-d) δ ppm 1.51 (9H, s), 4.15 (1H, br s), 4.46−4.60 (2H,
m), 4.98 (1H, d, J = 6.8 Hz), 5.23 (1H, d, J = 6.8 Hz), 7.08−7.47
(16H, m), 7.75 (1H, dd, J = 7.8, 1.0 Hz), 7.92 (2H, d, J = 8.1 Hz), 9.32
(1H, br s); 13C NMR (100 MHz, chloroform-d) δ ppm 28.3, 46.5,
76.1, 81.2, 89.6, 124.5, 125.7, 125.8, 125.9, 126.5, 127.3, 127.6, 127.8,
128.6, 128.7, 128.9, 130.2, 130.8, 133.3, 139.7, 142.7, 142.9, 154.7,
160.8, 165.5; m/z (ESI+) 563 ([M + H]+, 100%); HRMS calcd for
C34H35N4O4
+, 563.2653; found, 563.2639.
tert-Butyl (2-(4-((((4R,5S)-4,5-Diphenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (14k). To a
solution of (1S,2R)-2-amino-1,2-diphenylethanol (171 mg, 0.8
mmol) in THF (8 mL) was added isothiocyanate 2 (307 mg, 0.80
mmol); the mixture was then stirred at 20 °C for 18 h. Evaporation
gave a residue that was dissolved in acetone (4 mL); iodomethane
(0.10 mL, 1.60 mmol) was then added, and the solution was stirred at
20 °C for 6 h. The mixture was worked up as described for (R)-14h to
give an oil that was puriﬁed by ﬂash column chromatography on silica
gel (gradient elution from 1 to 5% of methanolic 2 M ammonia in
dichloromethane) and then with a SCX-2 cartridge (washed with
methanol and then eluted with 2 M ammonia in methanol) to give 14k
(421 mg, 85%) as a white solid, mp 121−123 °C; νmax (cm−1) 3277,
1653; 1H NMR (400 MHz, chloroform-d) δ ppm 1.51 (9H, s), 4.48−
4.59 (2H, m), 5.40 (1H, d, J = 8.9 Hz), 5.84 (1H, d, J = 8.9 Hz), 6.84−
6.92 (4H, m), 6.96−7.09 (6H, m), 7.10−7.22 (2H, m), 7.28 (1H, dd, J
= 7.2, 2.1 Hz), 7.35−7.46 (3H, m), 7.74 (1H, d, J = 7.6 Hz), 7.90 (2H,
d, J = 8.1 Hz), 9.36 (1H, br s); 13C NMR (100 MHz, chloroform-d) δ
ppm 28.3, 46.5, 71.9, 81.1, 85.8, 124.6, 125.7, 126.0, 126.2, 126.8,
127.4, 127.5, 127.6, 127.6, 127.8, 130.3, 130.7, 133.2, 136.4, 139.1,
143.1, 154.7, 161.6, 165.6; m/z (ESI+) 563 ([M + H]+, 100%); HRMS
calcd for C34H35N4O4
+, 563.2653; found, 563.2641.
(R)-tert-Butyl (2-(4-(((4-((1H-Imidazol-4-yl)methyl)-4,5-dihy-
drooxazol-2-yl)amino)methyl)benzamido)phenyl)carbamate
(R)-(14l). To a mixture of (R)-2-amino-3-(1H-imidazol-4-yl)propan-1-
ol dihydrochloride (123 mg, 0.574 mmol) in THF (10 mL) were
added potassium carbonate (0.16 mg, 1.15 mmol) and 2 (200 mg,
0.522 mmol). The mixture was stirred at 72 °C for 72 h. The mixture
was ﬁltered, and evaporation of the ﬁltrate gave a residue that was
dissolved in acetone (6 mL); iodomethane (0.065 mL, 1.04 mmol)
was then added, and the solution was stirred at 20 °C for 18 h. The
mixture was worked up as described for (R)-14h to give a solid that
was puriﬁed by ﬂash column chromatography on silica gel (gradient
elution from 2 to 20% of methanolic 2 M ammonia in dichloro-
methane) to give (R)-14l (110 mg, 43%) as a white solid, mp 159−
163 °C; νmax (cm
−1) 3664 (NH), 3382 (NH), 1679, 1641; 1H NMR
(500 MHz, DMSO-d6) δ ppm 1.46 (9H, s), 2.62 (1H, dd, J = 15.4, 5.8
Hz), 3.09 (1H, dd, J = 15.4, 7.4 Hz), 3.75 (1H, dd, J = 11.0, 5.5 Hz),
4.24 (1H, dd, J = 11.0, 7.0 Hz), 4.31 (2H, d, J = 6.0 Hz), 4.75 (1H, m),
6.53 (1H, t, J = 6.0 Hz), 6.62 (1H, s), 6.66 (1H, d, J = 7.4 Hz), 7.12−
7.26 (2H, m), 7.41 (2H, d, J = 8.2 Hz), 7.49−7.61 (3H, m), 7.91 (2H,
d, J = 8.0 Hz), 8.69 (1H, br s), 9.81 (1H, s); 13C NMR (125 MHz,
DMSO-d6) δ ppm 28.5, 29.6, 43.1, 50.7, 55.0, 80.1, 119.8, 124.4, 124.6,
126.0, 126.4, 127.4, 128.0, 130.3, 131.4, 132.1, 133.0, 134.7, 145.5,
153.9, 157.9, 165.6; m/z (ESI+) 491 ([M + H]+, 100%); HRMS calcd
for C26H31N6O4
+, 491.2401; found, 491.2390.
(S)-tert-Butyl (2-(4-(((4-((1H-Imidazol-4-yl)methyl)-4,5-dihy-
drooxazol-2-yl)amino)methyl)benzamido)phenyl)carbamate
(S)-(14l). To a mixture of (S)-2-amino-3-(1H-imidazol-4-yl)propan-1-
ol dihydrochloride (178 mg, 0.83 mmol) in THF (6 mL) was added
potassium carbonate (230 mg, 1.67 mmol) followed by a solution of 2
(319 mg, 0.833 mmol) in THF (6 mL). The resulting mixture was
stirred at 20 °C for 17 h and was then heated at reﬂux for 72 h. The
mixture was ﬁltered, and evaporation of the ﬁltrate gave a residue that
was dissolved in acetone (6 mL); iodomethane (0.104 mL, 1.67
mmol) was then added, and the solution was stirred at 20 °C for 5 h.
The mixture was worked up as described for (R)-14h to give a solid
that was puriﬁed by ﬂash column chromatography on silica gel
(gradient elution from 2 to 20% of methanolic 2 M ammonia in
dichloromethane) to give (S)-14l (135 mg, 33%) as a white solid, mp
155−157 °C; νmax (cm−1) 3310, 1635; 1H NMR (400 MHz, methanol-
d4) δ ppm 1.51 (9H, s), 2.74 (1H, ddd, J = 15.6, 5.5, 1.0 Hz), 3.23
(1H, ddd, J = 15.6, 7.3, 1.0 Hz), 3.87 (1H, dd, J = 11.4, 5.3 Hz), 4.35
(1H, dd, J = 11.4, 6.7 Hz), 4.43 (2H, s), 4.95 (1H, m), 6.69 (1H, s),
7.19−7.29 (2H, m), 7.40−7.49 (3H, m), 7.57 (1H, s), 7.63 (1H, m),
7.94 (2H, d, J = 8.1 Hz); 13C NMR (100 MHz, methanol-d4) δ ppm
27.2, 28.8, 42.9, 50.6, 54.8, 80.3, 118.8, 124.3, 124.9, 125.7, 126.0,
126.9, 127.4, 130.3, 130.9, 131.6, 132.7, 134.6, 144.6, 154.9, 158.8,
166.7; m/z (ESI+) 491 ([M + H]+, 100%); HRMS calcd for
C26H31N6O4
+, 491.2401; found, 491.2382.
(S)-N-(2-Aminophenyl)-4-(((4-benzyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (15a). To a solution of 14a (0.44 g,
0.88 mmol) in dichloromethane (3.4 mL) was added triﬂuoroacetic
acid (0.6 mL). The solution was stirred at 20 °C for 5 h; then,
triﬂuoroacetic acid (0.20 mL) was added, and the solution was stirred
at 20 °C for a further 30 min. To the mixture were then added
dichloromethane (50 mL) and saturated aqueous sodium hydrogen
carbonate (30 mL), and the mixture was then stirred vigorously for 5
min. The organic layer was washed with brine (30 mL), dried
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(Na2SO4), and evaporated. The residue was puriﬁed by column
chromatography on silica gel (1:1:98 ammonia (30% aqueous)/
methanol/ethyl acetate) to give 15a as a white solid (0.167 g, 47%),
mp 146−147 °C; [α]D25 + 8.8 (c 0.5, methanol); νmax (cm−1) 3202,
1674, 1647; 1H NMR (500 MHz, chloroform-d) δ ppm 2.62 (1H, dd,
J = 13.5, 8.3 Hz), 3.00 (1H, dd, J = 13.5, 5.0 Hz), 3.87 (2H, br s), 3.98
(1H, t, J = 7.7 Hz), 4.18 (1H, t, J = 8.1 Hz), 4.26 (1H, m), 4.32−4.44
(2H, m), 6.74−6.85 (2H, m), 7.07 (1H, t, J = 7.3 Hz), 7.15 (2H, d, J =
7.1 Hz), 7.20 (1H, t, J = 6.9 Hz), 7.23−7.36 (5H, m), 7.81 (2H, d, J =
7.4 Hz), 8.22 (1H, br s); m/z (CI) 401 ([M + H]+, 100%); HRMS
calcd for C24H25N4O2
+, 401.1972; found, 401.1963.
(S)-N-(2-Aminophenyl)-4-(((4-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (S)-(15b). To a solution of (S)-14b
(103 mg, 0.21 mmol) in dichloromethane (0.90 mL) was added
triﬂuoroacetic acid (0.10 mL). The solution was stirred at 20 °C for
1.5 h; then, triﬂuoroacetic acid (0.05 mL) was added, and the solution
was stirred at 20 °C for a further 2.5 h. The reaction was diluted with
dichloromethane (10 mL) and saturated aqueous sodium hydrogen
carbonate (10 mL) and then stirred vigorously for 5 min. The organic
layer washed with saturated aqueous sodium hydrogen carbonate (10
mL), dried (Na2SO4), and evaporated. Puriﬁcation by column
chromatography on silica gel (1:1:98 ammonia (30% aqueous)/
methanol/ethyl acetate) gave (S)-15b as a white solid (60 mg, 74%),
mp 85−86 °C; [α]D25 + 12.2 (c 0.5, methanol); νmax (cm−1) 3254,
1649; 1H NMR (500 MHz, chloroform-d) δ ppm 3.91 (2H, br s), 4.09
(1H, t, J = 7.6 Hz), 4.42 (2H, br s), 4.62 (1H, t, J = 8.5 Hz), 5.09 (1H,
t, J = 7.9 Hz), 6.75−6.88 (2H, m), 7.09 (1H, t, J = 7.6 Hz), 7.20−7.38
(8H, m), 7.80 (2H, d, J = 6.3 Hz), 8.32 (1H, br s); 13C NMR (125
MHz, chloroform-d) δ ppm 46.9, 67.9, 75.7, 118.7, 120.0, 125.0, 125.8,
126.8, 127.6, 127.7, 127.8, 128.1, 129.0, 133.5, 141.3, 143.6, 144.0,
162.1, 166.2; m/z (ESI−) 385 ([M − H]−, 100%); HRMS calcd for
C23H21N4O2
−, 385.1670; found, 385.1673.
(R)-N-(2-Aminophenyl)-4-(((4-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (R)-(15b). To a solution of (R)-14b
(150 mg, 0.308 mmol) in dichloromethane (5 mL) was added
triﬂuoroacetic acid (0.50 mL, 6.2 mmol) dropwise; then, the mixture
was stirred at 20 °C for 3 h. Saturated aqueous sodium hydrogen
carbonate (20 mL) was then added, and the mixture was extracted
with ethyl acetate (2 × 30 mL). The combined organic layers were
washed with brine (30 mL), dried (Na2SO4), and evaporated to give a
white solid that was puriﬁed by column chromatography on silica gel
(1:1:98 ammonia (30% aqueous)/methanol/ethyl acetate) to give
(R)-15b as a white solid (38 mg, 32%), mp 115−118 °C; [α]D25 −14.0
(c 1.0, methanol); νmax (cm
−1) 3287, 1649; 1H NMR (300 MHz,
chloroform-d) δ ppm 4.04 (1H, t, J = 7.5 Hz), 4.11 (1H, br s), 4.33
(2H, s), 4.56 (1H, t, J = 8.6 Hz), 5.02 (1H, dd, J = 8.8, 7.3 Hz), 6.68−
6.61 (2H, m), 7.04 (1H, td, J = 7.6, 1.0 Hz), 7.12−7.36 (8H, m), 7.73
(2H, d, J = 7.9 Hz), 8.52 (1H, br s); 13C NMR (75 MHz, chloroform-
d) δ ppm 46.5, 67.4, 75.5, 118.3, 119.6, 124.6, 125.8, 126.6, 127.4,
127.6, 127.9, 128.8, 133.1, 141.2, 143.2, 143.6, 161.9, 166.1; m/z
(ESI+) 387 ([M + H]+, 100%); HRMS calcd for C23H23N4O2
+,
387.1816; found, 387.1808.
(S)-N-(2-Aminophenyl)-4-(((4-(pyridin-3-yl)-4,5-dihydrooxa-
zol-2-yl)/amino)methyl)benzamide (15c). To a solution of 14c
(80 mg, 0.164 mmol) in dichloromethane (1.0 mL) was added
triﬂuoroacetic acid (0.25 mL, 3.25 mmol). The resulting solution was
stirred at 20 °C for 1.5 h. The mixture was worked up as for (R)-15b
to give a solid that was puriﬁed by ﬂash column chromatography on
silica gel (gradient elution from 2 to 10% of methanolic 2 M ammonia
in dichloromethane) to give 15c (38 mg, 60%) as a white solid, mp
89−90 °C (dec.); [α]D25 −20.0 (c 1.0, methanol); νmax (cm−1) 3214,
1652; 1H NMR (400 MHz, methanol-d4) δ ppm 4.12 (1H, dd, J = 8.3,
6.6 Hz), 4.42−4.58 (2H, m), 4.73 (1H, dd, J = 9.1, 8.3 Hz), 5.16 (1H,
dd, J = 9.1, 6.6 Hz), 6.79 (1H, td, J = 7.6, 1.0 Hz), 6.93 (1H, dd, J =
8.1, 1.0 Hz), 7.10 (1H, td, J = 7.6, 1.3 Hz), 7.22 (1H, d, J = 7.6 Hz),
7.41 (1H, dd, J = 7.8, 5.1 Hz), 7.53 (2H, d, J = 8.1 Hz), 7.70 (1H, dt, J
= 7.8, 1.8 Hz), 8.00 (2H, d, J = 8.1 Hz), 8.41−8.49 (2H, m); 13C NMR
(100 MHz, methanol-d4) δ ppm 45.5, 64.5, 74.6, 117.3, 118.3, 123.9,
126.3, 126.9, 127.1, 127.7, 127.7, 133.1, 135.0, 140.1, 142.4, 143.3,
147.2, 147.7, 163.3, 167.3; m/z (ESI+) 388 ([M + H]+, 100%); HRMS
calcd for C22H22N5O2
+, 388.1768; found, 388.1774.
N-(2-Aminophenyl)-4-(((4-(4-ﬂuorophenyl)-4,5-dihydrooxa-
zol-2-yl)amino)methyl)benzamide (15d). To a solution of 14d
(220 mg, 0.436 mmol) in dichloromethane (6 mL) was added
triﬂuoroacetic acid (0.67 mL, 8.7 mmol) dropwise; then, the mixture
was stirred at 20 °C for 3 h. The mixture was then worked up as for
(R)-15b to give a solid that was puriﬁed by column chromatography
on silica gel (1:1:98 ammonia (30% aqueous)/methanol/ethyl acetate)
and again (1:6:93 ammonia (30% aqueous)/methanol/ethyl acetate)
to give 15d as a white solid (108 mg, 61%), mp 104−108 °C; νmax
(cm−1) 3245, 1649; 1H NMR (500 MHz, chloroform-d) δ ppm 4.02
(1H, m), 4.09 (2H, br s), 4.39 (2H, s), 4.60 (1H, m), 5.08 (1H, m),
6.71−6.86 (2H, m), 6.93−7.03 (2H, m), 7.07 (1H, m), 7.12−7.22
(2H, m), 7.22−7.36 (3H, m), 7.70−7.87 (2H, m), 8.44 (1H, br s); 13C
NMR (125 MHz, chloroform-d) δ ppm 46.4, 66.7, 75.3, 115.3 (d, J =
22.1 Hz), 118.1, 119.5, 124.4, 125.5, 127.2, 127.6, 127.9 (d, J = 8.6
Hz), 133.0, 139.2, 140.9, 142.9, 162.0 (d, J = 245.7 Hz), 161.7), 165.7;
m/z (ESI+) 405 ([M + H]+, 100%); HRMS calcd for C23H22FN4O2
+,
405.1721; found, 405.1710.
N-(2-Aminophenyl)-4-(((4-(3-ﬂuorophenyl)-4,5-dihydrooxa-
zol-2-yl)amino)methyl)benzamide (15e). To a solution of 14e
(190 mg, 0.377 mmol) in dichloromethane (3 mL) was added
triﬂuoroacetic acid (0.60 mL, 7.5 mmol) dropwise. The resulting
solution was stirred at 20 °C for 2 h. The mixture was then worked up
as for (R)-15b to give a solid that was puriﬁed by ﬂash column
chromatography on silica gel (gradient elution from 1 to 6% of
methanolic 2 M ammonia in dichloromethane) to give 15e (131 mg,
86%) as a white solid, mp 84−86 °C; νmax (cm−1) 3276, 1652; 1H
NMR (400 MHz, methanol-d4) δ ppm 4.05 (1H, dd, J = 8.2, 6.4 Hz),
4.41−4.56 (2H, m), 4.68 (1H, dd, J = 9.1, 8.3 Hz), 5.09 (1H, dd, J =
9.0, 6.4 Hz), 6.79 (1H, td, J = 7.6, 1.0 Hz), 6.88−7.02 (3H, m), 7.03−
7.14 (2H, m), 7.21 (1H, d, J = 7.8 Hz), 7.33 (1H, td, J = 7.9, 5.9 Hz),
7.53 (2H, d, J = 8.1 Hz), 8.00 (2H, d, J = 8.1 Hz); 13C NMR (100
MHz, methanol-d4) δ ppm 45.6, 66.2, 74.9, 112.7 (d, J = 22.4 Hz),
113.7 (d, J = 20.8 Hz), 117.3, 118.3, 121.9 (d, J = 3.2 Hz), 124.0,
126.3, 127.0, 127.2, 127.7, 130.0 (d, J = 8.0 Hz), 133.0, 142.4, 143.4,
146.8 (d, J = 7.2 Hz), 163.0 (d, J = 245.3 Hz), 163.0, 167.2; m/z
(ESI+) 405 ([M + H]+, 100%); HRMS calcd for C23H22FN4O2
+,
405.1721; found, 405.1723; 94% purity by LC-MS.
N-(2-Aminophenyl)-4-(((4-(4-(triﬂuoromethyl)phenyl)-4,5-di-
hydrooxazol-2-yl)amino)methyl)benzamide (15f). To a solution
of 14f (190 mg, 0.343 mmol) in dichloromethane (4 mL) was added
triﬂuoroacetic acid (0.53 mL, 6.85 mmol). The resulting solution was
stirred at 20 °C for 2.5 h. The mixture was then worked up as for (R)-
15b to give a solid that was puriﬁed by ﬂash column chromatography
on silica gel (gradient elution from 1 to 6% of methanolic 2 M
ammonia in dichloromethane) to give 15f (110 mg, 71%) as a white
solid, mp 198−199 °C; νmax (cm−1) 3265, 1653; 1H NMR (500 MHz,
methanol-d4) δ ppm 4.08 (1H, dd, J = 8.2, 6.6 Hz), 4.44−4.58 (2H,
m), 4.73 (1H, dd, J = 9.2, 8.2 Hz), 5.18 (1H, dd, J = 9.2, 6.6 Hz), 6.80
(1H, t, J = 7.4 Hz), 6.93 (1H, d, J = 8.0 Hz), 7.11 (1H, t, J = 7.1 Hz),
7.22 (1H, d, J = 7.7 Hz), 7.43 (2H, d, J = 8.0 Hz), 7.54 (2H, d, J = 8.0
Hz), 7.64 (2H, d, J = 8.0 Hz), 8.01 (2H, d, J = 8.0 Hz); 13C NMR (125
MHz, methanol-d4) δ ppm 45.6, 66.3, 74.8, 117.4, 118.3, 124.3 (q, J =
271.0 Hz), 124.0, 125.1 (q, J = 3.9 Hz), 126.3, 126.7, 127.0, 127.2,
127.7, 129.2 (q, J = 32.4 Hz), 133.0, 142.4, 143.4, 148.3, 163.2, 167.2;
m/z (ESI+) 455 ([M + H]+, 100%); HRMS calcd for C24H22F3N4O2
+,
455.1689; found, 455.1686; 92% purity by LC-MS.
(S)-N-(2-Aminophenyl)-4-(((4-(4-hydroxyphenyl)-4,5-dihy-
drooxazol-2-yl)amino)methyl)benzamide (15g). To a solution of
14g (250 mg, 0.497 mmol) in dichloromethane (6 mL) was added
triﬂuoroacetic acid (0.77 mL, 10 mmol). The resulting solution was
stirred at 20 °C for 2.5 h. The mixture was then worked up as for (R)-
15b to give a solid that was puriﬁed by ﬂash column chromatography
on silica gel (gradient elution from 1 to 10% of methanolic 2 M
ammonia in dichloromethane) to give 15g (141 mg, 70%) as a white
solid, mp 158−160 °C; [α]D25 + 17.6 (c 0.5, methanol); νmax (cm−1)
3262, 1646; 1H NMR (400 MHz, methanol-d4) δ ppm 4.03 (1H, dd, J
= 8.0, 6.8 Hz), 4.39−4.54 (2H, m), 4.62 (1H, dd, J = 9.0, 8.0 Hz), 4.99
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(1H, dd, J = 9.0, 6.8 Hz), 6.74 (2H, d, J = 8.6 Hz), 6.79 (1H, td, J =
7.6, 1.0 Hz), 6.92 (1H, dd, J = 7.8, 1.2 Hz), 7.02−7.14 (3H, m), 7.22
(1H, d, J = 7.8 Hz), 7.52 (2H, d, J = 8.1 Hz), 7.98 (2H, d, J = 8.3 Hz);
13C NMR (100 MHz, methanol-d4) δ ppm 45.6, 66.3, 75.3, 114.9,
117.4, 118.3, 124.0, 126.3, 127.0, 127.1, 127.2, 127.6, 132.9, 134.4,
142.3, 143.6, 156.5, 162.5, 167.3; m/z (ESI+) 403 ([M + H]+, 100%);
HRMS calcd for C23H23N4O3
+, 403.1765; found, 403.1765.
(R)-N-(2-Aminophenyl)-4-(((5-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (R)-(15h). To a solution of (R)-14h
(280 mg, 0.575 mmol) in dichloromethane (4 mL) was added
triﬂuoroacetic acid (0.60 mL, 7.8 mmol) dropwise. The resulting
solution was stirred at 20 °C for 3.5 h. The mixture was then worked
up as for (R)-15b to give a solid that was puriﬁed by ﬂash column
chromatography on silica gel (gradient elution from 1.6 to 8% of
methanolic 2 M ammonia in dichloromethane) to give a white solid
(140 mg). Further puriﬁcation by MDAP gave (R)-15h (75 mg, 34%)
as a white solid, mp 196−197 °C; [α]D25 −23.0 (c 1.0, methanol); νmax
(cm−1) 3398, 3238, 3340, 1668, 1641; 1H NMR (400 MHz, DMSO-
d6) δ ppm 3.44 (1H, dd, J = 12.2, 6.6 Hz), 4.04 (1H, dd, J = 12.2, 9.2
Hz), 4.38 (2H, s), 4.90 (2H, br s, NH2), 5.51 (1H, dd, J = 9.2, 6.6 Hz),
6.62 (1H, t, J = 7.3 Hz,), 6.80 (1H, d, J = 7.8 Hz), 6.98 (1H, t, J = 7.3
Hz), 7.10−7.24 (2H, m), 7.26−7.36 (3H, m), 7.40 (2H, t, J = 7.1 Hz),
7.46 (2H, d, J = 8.0 Hz), 7.96 (2H, d, J = 8.0 Hz), 9.64 (1H, s); 13C
NMR (100 MHz, DMSO-d6) δ ppm 46.1, 61.2, 80.3, 116.6, 116.8,
123.9, 125.9, 126.9, 127.1, 127.3, 128.2, 128.3, 129.1, 133.5, 142.2,
143.6, 144.2, 160.5, 165.7; m/z (ESI+) 387 ([M + H]+, 100%); HRMS
calcd for C23H23N4O2
+, 387.1816; found, 387.1813.
(S)-N-(2-Aminophenyl)-4-(((5-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (S)-(15h). To a solution of (S)-14h
(0.275 g, 0.565 mmol) in dichloromethane (6 mL) was added
triﬂuoroacetic acid (0.90 mL, 11.5 mmol). The resulting solution was
stirred at 20 °C for 3 h. The mixture was then worked up as for (R)-
15b to give a solid that was puriﬁed by MDAP to give (S)-15h (75 mg,
34%) as a cream solid, mp 214−215 °C; [α]D25 + 22.0 (c 0.5,
methanol); νmax (cm
−1) 3338, 3237, 1668, 1641; 1H NMR (500 MHz,
DMSO-d6) δ ppm 3.49 (1H, dd, J = 11.8, 7.0 Hz), 4.08 (1H, dd, J =
11.8, 9.1 Hz), 4.41 (2H, s), 4.91 (2H, br s), 5.61 (1H, t, J = 8.0 Hz),
6.62 (1H, t, J = 7.3 Hz), 6.80 (1H, d, J = 7.7 Hz), 6.99 (1H, t, J = 7.0
Hz), 7.19 (1H, d, J = 7.4 Hz), 7.31−7.38 (3H, m), 7.39−7.44 (2H, m),
7.46 (2H, d, J = 8.0 Hz), 7.97 (2H, d, J = 7.7 Hz), 9.67 (1H, s); 13C
NMR (125 MHz, DMSO-d6) δ ppm 46.0, 59.5, 80.9, 116.6, 116.7,
123.8, 126.1, 126.9, 127.2, 127.3, 128.3, 128.6, 129.1, 133.7, 141.3,
143.6, 143.6, 160.7, 165.6; m/z (ESI+) 387 ([M + H]+, 100%); HRMS
calcd for C23H23N4O2
+, 387.1816; found, 387.1822.
N-(2-Aminophenyl)-4-(((4,4-diphenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (15i). To a solution of 14i (280 mg,
0.498 mmol) in dichloromethane (6 mL) was added triﬂuoroacetic
acid (0.80 mL, 10 mmol). The resulting solution was stirred at 20 °C
for 2.5 h. The mixture was then worked up as for (R)-15b to give a
solid that was puriﬁed by ﬂash column chromatography on silica gel
(gradient elution from 1 to 6% of methanolic 2 M ammonia in
dichloromethane) to give 15i (135 mg, 59%) as a white solid, mp
176−177 °C; νmax (cm−1) 3194, 1670, 1649; 1H NMR (400 MHz,
methanol-d4) δ ppm 4.54 (2H, s), 4.79 (2H, s), 6.79 (1H, td, J = 7.6,
0.8 Hz), 6.92 (1H, dd, J = 8.1, 1.2 Hz), 7.10 (1H, td, J = 7.7, 1.3 Hz),
7.17−7.37 (11H, m), 7.49 (2H, d, J = 8.2 Hz), 7.96 (2H, d, J = 8.2
Hz); 13C NMR (100 MHz, methanol-d4) δ ppm 45.4, 76.4, 80.0,
117.4, 118.3, 124.0, 126.3, 126.6, 126.6, 127.0, 127.1, 127.6, 127.8,
132.9, 142.4, 143.6, 146.4, 161.4, 167.2; m/z (ESI+) 463 ([M + H]+,
100%); HRMS calcd for C29H27N4O2
+, 463.2129; found, 463.2118.
N-(2-Aminophenyl)-4-((((4S,5S)-4,5-diphenyl-4,5-dihydroox-
azol-2-yl)amino)methyl)benzamide (15j). To a solution of 14j
(155 mg, 0.275 mmol) in dichloromethane (2 mL) was added
triﬂuoroacetic acid (0.42 mL, 5.5 mmol) dropwise. The resulting
solution was stirred at 20 °C for 2 h. The mixture was then worked up
as for (R)-15b to give a solid that was puriﬁed by ﬂash column
chromatography on silica gel (gradient elution from 1 to 6% of
methanolic 2 M ammonia in dichloromethane) to give 15j (125 mg,
98%) as a white solid, mp 110−113 °C; [α]D25 −33.2 (c 1.0, methanol);
νmax (cm
−1) 3264, 1657; m/z (ESI+) 463 ([M + H]+, 100%); 1H NMR
(400 MHz, methanol-d4) δ ppm 4.46−4.63 (2H, m), 4.89 (1H, m),
5.23 (1H, d, J = 6.6 Hz), 6.79 (1H, t, J = 7.5 Hz), 6.92 (1H, dd, J = 8.1,
1.3 Hz), 7.10 (1H, td, J = 7.7, 1.5 Hz), 7.19−7.44 (11H, m), 7.57 (2H,
d, J = 8.3 Hz), 8.02 (2H, d, J = 8.1 Hz); 13C NMR (100 MHz,
methanol-d4) δ ppm 45.6, 75.9, 89.3, 117.4, 118.3, 124.0, 125.3, 126.2,
126.3, 127.1, 127.2, 127.4, 127.7, 128.2, 128.4, 128.5, 133.0, 139.9,
142.4, 142.8, 143.4, 162.0, 167.3; HRMS calcd for C29H27N4O2
+,
463.2129; found, 463.2128; 94% purity by LC-MS.
N-(2-Aminophenyl)-4-((((4R,5S)-4,5-diphenyl-4,5-dihydroox-
azol-2-yl)amino)methyl)benzamide (15k). To a solution of 14k
(414 mg, 0.736 mmol) in dichloromethane (6 mL) was added
triﬂuoroacetic acid (1.15 mL, 15 mmol) dropwise. The resulting
solution was stirred at 20 °C for 5 h. To the mixture were added
saturated aqueous sodium hydrogen carbonate (20 mL) and ethyl
acetate (50 mL). After extraction, the aqueous layer was separated and
extracted with another portion of ethyl acetate (20 mL). The
combined organic layers were washed with brine, dried (Na2SO4), and
evaporated to give a white solid. Puriﬁcation by ﬂash column
chromatography on silica gel (gradient elution from 3 to 6% of
methanolic 2 M ammonia in dichloromethane) followed by MDAP
gave 15k (107 mg, 31%) as a white solid, mp 112−113 °C; [α]D25 +
51.6 (c 0.5, methanol); νmax (cm
−1) 3270, 1652; 1H NMR (400 MHz,
chloroform-d) δ ppm 3.90 (2H, br s), 4.39−4.63 (2H, m), 5.38 (1H, d,
J = 8.8 Hz), 5.81 (1H, d, J = 8.8 Hz), 6.73−6.94 (6H, m), 6.94−7.17
(7H, m), 7.30 (1H, m), 7.40 (2H, d, J = 7.8 Hz), 7.84 (2H, d, J = 7.8
Hz), 8.30 (1H, br s); 13C NMR (100 MHz, chloroform-d) δ ppm 46.5,
72.0, 85.7, 118.3, 119.7, 124.6, 125.4, 126.2, 126.8, 127.2, 127.4, 127.5,
127.5, 127.6, 127.6, 127.7, 133.2, 136.4, 139.2, 140.9, 143.3, 161.5,
165.8; m/z (ESI+) 463 ([M + H]+, 100%); HRMS calcd for
C29H27N4O2
+, 463.2129; found, 463.2128.
(R)-4-(((4-((1H-Imidazol-4-yl)methyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)-N-(2-aminophenyl)benzamide (R)-(15l). To a
suspension of (R)-14l (100 mg, 0.204 mmol) in dichloromethane (2
mL) was added triﬂuoroacetic acid (0.31 mL, 4.1 mmol) dropwise.
The resulting solution was stirred at 20 °C for 2 h and then
evaporated, and the residue was puriﬁed by MDAP to (R)-15l (43 mg,
54%) as a white solid, mp 191−193 °C; [α]D25 + 6.3 (c 1.0, methanol);
νmax (cm
−1) 3227, 1673, 1627; 1H NMR (500 MHz, methanol-d4) δ
ppm 2.74 (1H, dd, J = 15.5, 5.4 Hz), 3.24 (1H, dd, J = 15.5, 7.3 Hz),
3.88 (1H, dd, J = 11.3, 5.2 Hz), 4.36 (1H, dd, J = 11.1, 6.7 Hz), 4.43
(2H, s), 4.95 (1H, m), 6.70 (1H, s), 6.79 (1H, t, J = 7.3 Hz), 6.93 (1H,
d, J = 7.7 Hz), 7.10 (1H, m), 7.21 (1H, d, J = 7.4 Hz), 7.45 (2H, d, J =
7.7 Hz), 7.59 (1H, s), 7.97 (2H, d, J = 8.0 Hz); 13C NMR (125 MHz,
methanol-d4) δ ppm 28.8, 42.9, 50.6, 54.7, 117.3, 118.3, 118.8, 123.9,
126.2, 126.8, 127.1, 127.6, 130.9, 132.8, 134.6, 142.4, 144.2, 158.8,
167.3; m/z (ESI+) 391 ([M + H]+, 100%); HRMS calcd for
C21H23N6O2
+, 391.1877; found, 391.1881.
(S)-4-(((4-((1H-Imidazol-4-yl)methyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)-N-(2-aminophenyl)benzamide (S)-(15l). To a
suspension of 14k (130 mg, 0.265 mmol) in dichloromethane (2 mL)
was added triﬂuoroacetic acid (0.20 mL, 2.6 mmol) dropwise. The
resulting solution was stirred at 20 °C for 3 h; then, additional
triﬂuoroacetic acid (0.20 mL, 2.6 mmol) was added, and the mixture
stirred at 20 °C for 2 h. Addition of saturated aqueous sodium
hydrogen carbonate (15 mL) and then ethyl acetate (20 mL) gave an
insoluble white precipitate. The organic layer was separated, and the
aqueous layer was adjusted to pH 10 with sodium hydroxide (2M) and
then extracted with 1:4 ethanol/chloroform (4 × 25 mL). The
combined organic layers were washed with brine, dried (Na2SO4), and
evaporated to give a gray solid (40 mg). LC-MS showed the product
was dissolved in the aqueous layer. The aqueous layer was passed over
a 10 g SCX-2 cartridge, which was then washed with methanol (100
mL) and eluted with 2 M ammonia/methanol (100 mL), but LC-MS
showed the product to be in the eluent and methanolic washing
fraction. The methanol and water were evaporated to give a white solid
that was stirred with 1:9 methanol/dichloromethane for 30 min and
ﬁltered, and the ﬁltrate was evaporated to give a white solid that was
puriﬁed by MDAP to give (S)-15l (23 mg, 22%) as a white solid, mp
192−194 °C; [α]D25 −18.0 (c 0.1, methanol); νmax (cm−1) 3241, 1655;
1H NMR (400 MHz, methanol-d4) δ ppm 2.74 (1H, ddd, J = 15.5, 5.5,
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1.0 Hz), 3.24 (1H, ddd, J = 15.5, 7.4, 1.0 Hz), 3.87 (1H, dd, J = 11.3,
5.1 Hz), 4.35 (1H, dd, J = 11.3, 6.8 Hz), 4.43 (2H, s), 4.95 (1H, m),
6.69 (1H, s), 6.79 (1H, t, J = 7.2 Hz), 6.92 (1H, dd, J = 8.1, 1.2 Hz),
7.09 (1H, m), 7.20 (1H, d, J = 7.6 Hz), 7.44 (2H, d, J = 8.3 Hz), 7.57
(1H, s), 7.96 (2H, d, J = 8.1 Hz); 13C NMR (125 MHz, DMSO-d6) δ
ppm 29.5, 43.1, 50.7, 55.0, 116.6, 116.7, 119.9, 123.8, 126.9, 127.1,
127.2, 128.2, 131.4, 133.4, 134.6, 143.6, 144.9, 157.9, 165.6; m/z
(ESI+) 391 ([M + H]+, 100%); HRMS calcd for C21H23N6O2
+,
391.1877; found, 391.1878.
In Vitro HDAC Inhibition Assay. Recombinant HDAC isoforms
were used. HDAC2 (1−488, His-tag), HDAC3-NCoR1, HDAC6
(His-tag), Fluor-de-Lys SIRT1, Fluor-de-Lys developer II, and TSA
were purchased from Enzo Life Sciences, and porcine pancreatic
trypsin (type IX-S), from Sigma. HDAC1 (C-Flag) was purchased
from Tebu Bio. HDAC8 was expressed in Escherichia coli BL21 cells
and puriﬁed with a His-tag, which was removed prior to ﬁnal
puriﬁcation by size exclusion chromatography. Boc-Lys(Ac)-7-amino-
4-methylcoumarin (MAL) was synthesized according to the
literature.59 The in vitro HDAC assay used was based on a
homogeneous ﬂuorogenic HDAC assay.60 Inhibitor solutions were
prepared by serial dilution of a 5 mM DMSO stock solution with assay
buﬀer. In a 96-well white NBS microplate was added puriﬁed
recombinant HDAC enzyme (HDAC1, 120 ng; HDAC2, 85 ng;
HDAC3-NCoR1, 25 ng; HDAC6, 280 ng; HDAC8, 400 ng) in 20 μL
of assay buﬀer comprising 50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7
mM KCl, 1 mM MgCl2, 1 mg/mL BSA. To each well was added
inhibitor solution (10 μL). After incubation at 20−23 °C for the
appropriate time (HDAC1: 1 h; HDAC2, HDAC3, and HDAC6: 3 h;
HDAC8: 15 min), the ﬂuorescent substrate was added (for HDAC1,
HDAC2, HDAC3-NCoR1, and HDAC8: MAL (20 μL) to give
concentrations of 60, 80, 14, and 200 μM and for HDAC6 and Fluor-
de-Lys SIRT1 to give a concentration of 13 μM), and the plate was
incubated for 60 min at 37 °C. A developer solution (for HDAC1,
HDAC2, HDAC3-NCoR1, and HDAC8: 50 μL of 10 mg/mL trypsin
and 2 μM TSA in assay buﬀer; for HDAC6 Fluor-de-Lys developer II
and 2 μM TSA in 50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM
KCl, 1 mM MgCl2) was then added, and the plate incubated for 30
min at 20 °C before the ﬂuorescence was measured on a BMG
FLUOstar Optima plate reader with excitation at 380 nm and emission
at 460 nm.
Determination of IC50 Values. OriginPro 8 was used to
determine IC50 values from the sigmoidal line ﬁtted to a graph of
log[concentration] against the average percentage inhibition from two
independent experiments, with at least six diﬀerent concentrations.
The SEM is the calculated standard error in the IC50 value of the ﬁtted
line.
Calculation and Measurement of Physicochemical Proper-
ties. Chrom log D and Chrom log P values43 and cell permeability
(artiﬁcial membrane permeability)44 were measured using procedures
previously described. Solubility was measured using chemiluminescent
nitrogen detection.45
Cellular Histone H3 Acetylation Assay and Analysis of Cell
Cycle Phases and Apoptosis. Cell Culture and Application of
Compounds. Human PC-3 (epithelial prostate-derived adenocarcino-
ma) and human U937 (human leukemic monocyte lymphoma) cell
lines were cultured in a humidiﬁed incubator at 37 °C and 5% CO2.
PC-3 cells were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% v/v fetal bovine serum (Life
Technologies) and L-glutamine−penicillin−streptomycin solution
(Sigma). The U937 cell line was maintained in RPMI 1640 medium
supplemented with 10% v/v fetal bovine serum (Life Technologies)
and L-glutamine−penicillin−streptomycin solution (Sigma). For both
cell lines, cell density was adjusted to 1 × 106 cells in culture medium
(10 mL) in 25 mL tissue culture ﬂasks. A 10 mM stock solution of
each HDAC inhibitor in DMSO was serially diluted, with the ﬁnal
inhibitor concentration being 10 μM in fresh culture medium (500
μL); that solution was added dropwise to the PC-3 cultures and U937
cell suspensions, followed by gentle mixing and then incubation for 24
h. An equivalent volume of DMSO was added to control cell cultures.
Cell Cycle Analysis by Flow Cytometry. The method described by
Lea et al.61 was used. Brieﬂy, samples of 1 × 105 cells were taken
following 24 h incubation with each compound and ﬁxed in ethanol
(400 μL, 70% v/v) at −20 °C. Following centrifugation at 400g for 8
min, the pellet was resuspended in FITC/PI cell cycle stain (400 μL)
consisting of PI (40 μg, to stain for DNA content), FITC (5 μg/mL,
protein staining), and RNase1 (1 μg/mL). The mixture was incubated
at 37 °C for 30 min and then analyzed on a FACSCanto (Beckton
Dickenson) ﬂow cytometer. The FlowJo, v10.0.6, program (Tree Star
Inc.) was used to plot PI (FL2-A) against FITC (FL-1A) (x and y axes,
respectively) to determine the percentage of cells in each cell cycle
phase. Plotting (FL2-W) against (FL2-H) created a doublet
discriminator gate to exclude doublets from the analysis. The
percentage of cells in each cycle phase was calculated by applying
gates manually around cell populations for the cell cycle phases
indicated, as well as cell with sub-G1 DNA content.
Immunoblotting. PC-3 and U937 cell pellets containing 1 × 106
cells were resuspended in SDS loading buﬀer (50 μL), vortexed, and
heated for 5 min at 100 °C to denature the proteins. Samples were
diluted 1:50 in SDS loading buﬀer and resolved by electrophoresis
through polyacrylamide (4−12% w/v) Bis-Tris gels (Novex, Life
Technologies). Proteins in each gel were transferred to a Hybond-C
extra nitrocellulose membrane by electrophoresis at 25 V, 160 mA for
75 min. The nitrocellulose membrane was blocked with dried skim
milk (Marvel, 5% w/v) diluted in PBS−Tween 20 (0.05% v/v) and
kept for 1 h. After a PBS−Tween-20 rinse, the membrane was
immunoblotted with primary antibodies against histone H3 (DIH2),
acetylated histone H3 (Lys 9) (C5BII, Cell Signaling Technologies),
and cyclin E (HE12) (SC-247). Detection was performed with anti-
mouse or anti-rabbit horseradish peroxidase-conjugated secondary
antibodies (Dako or Santa Cruz), as appropriate, and ECL-plus
detection reagent (GE Healthcare). Images were acquired by exposure
to X-ray ﬁlm (GE Healthcare).
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